

CURRICULUM VITAE

Name: Wester, Hans-Jürgen Peter
Date of birth: January 21, 1962
Citizenship: German
Address: Chair of Pharmaceutical Radiochemistry
Faculties of Chemistry and Medicine
Technische Universität München
Walther-Meißner-Str. 3
85748 Garching, GERMANY
Phone: +49-(0)89-2891 2203 / 2212
Fax: +49-(0)89-2891 2204
E-Mail: h.j.wester@tum.de

Scientific career history

1992 Diploma (Chemistry/Radiochemistry), University of Cologne and Research Center Juelich (under G.Stöcklin)
1996 Ph.D., Radiopharmaceutical Chem., Research Center Juelich (under G.Stöcklin)
1995-2004 Scientific Assistant and Research Associate, Department of Nuclear Medicine, Technische Universität München (under M.Schwaiger)

Academic Appointments

2004-2010 Professor (C3) of Radiopharmaceutical Chemistry, TUM, Faculty of Medicine, Nuclear Medicine
Co-appointment at the Faculty of Chemistry
2010-present Full Professor (W3), Pharmaceutical Radiochemistry, TUM, 1st full appointment at the Faculty of Chemistry, 2nd full appointment at the Faculty of Medicine

Co-Speaker of the Collaborative Research Center (SFB 824) of the German Research Foundation

Member of the Board of the German Society for Nuclear Medicine (2009-2012)

Board of the Bavarian Society for Nuclear Medicine (since 2003)

Founder (2006), shareholder and CEO (2006-2015) SCINTOMICS GmbH (Germany).

Scientific focus/prominent developments: Development of Probes for Molecular Imaging and Targeted Therapy, Transfer of new Agents into Clinical Studies. Selected examples: [¹⁸F]Fluoroethyltyrosine ([¹⁸F]FET, 1998); the "Multimeric Peptide" Approach (1998); [¹⁸F]Diprenorphine ([¹⁸F]FDPN, 1999); RGD-peptides (with Roland Haubner; [¹⁸F]Galacto-RGD, 2001); The "Carbohydrated Peptide" Concept (2000); CXCR4 Chemokine Receptor Ligands (2007-...); In-Capillary Production of Radiopharmaceuticals (2008); Phosphinates for Ga-68-complexation (with Johannes Notni, 2010); F-18-fluorination without azeotropic drying (2010, patent), Ga-68-TRAP(RGD)₃ (patent), Ga-68-CPCR4.2 (Pentixafor, 2012, patent), F-18-FIBT (2012, Alzheimer Imaging Agent (with B.Yousefi patent application), new direct fluorination of unprotected acids (with B.Yousefi, 2013), New phosphinate based DOTA analogues for Lu and Cu labelling (with Johannes Notni, 2013); Pentixather (2014, with M.Schottelius), PSMA Inhibitors for Imaging and Therapy (ongoing), PSMA inhibitors for Radioguided Surgery (ongoing, with M.Schottelius), and Radiohybrid concept for 18F-Probes (2017, ongoing).

Publication List Wester, Hans-Jürgen Peter

h-index: 69 (Dec.2018); citations: 14,780

316. Heck MM, Tauber R, Schwaiger S, Retz M, D'Alessandria C, Maurer T, Gafita A, Wester HJ, Gschwend JE, Weber WA, Schwaiger M, Knorr K, Eiber M. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with (177)Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. *Eur Urol*. 2018 Nov 22. pii: S0302-2838(18)30873-X.
315. Grimmer T, Shi K, Diehl-Schmid J, Natale B, Drzezga A, Förster S, Förstl H, Schwaiger M, Yakushev I, Wester HJ, Kurz A, Yousefi BH. Correction: (18)F-FIBT may expand PET for β -amyloid imaging in neurodegenerative diseases. *Mol Psychiatry*. 2018 Nov 21. doi: 10.1038/s41380-018-0302-3.
314. Gafita A, Rauscher I, Retz M, Knorr K, Heck M, Wester HJ, D'Alessandria C, Weber WA, Eiber M, Tauber R. Early experience of rechallenge (177)Lu-PSMA radioligand therapy after an initial good response in patients with mCRPC. *J Nucl Med*. 2018 Nov 15. pii: jnumed.118.215715. doi: 10.2967/jnumed.118.215715.
313. Bouter Y, Meller B, Sahlmann CO, Wolf BJ, Langer L, Bankstahl JP, Wester HJ, Kropf S, Meller J, Bouter C. Immunohistochemical detection of chemokine receptor 4 expression in chronic osteomyelitis confirms specific uptake in 68Ga-Pentixafor-PET/CT. *Nuklearmedizin*. 2018 Sep;57(5):198-203.
312. Schottelius M, Wurzer A, Wissmiller K, Beck R, Koch M, Gkorpas D, Notni J, Buckle T, van Oosterom MN, Steiger K, Ntziachristos V, Schwaiger M, van Leeuwen FWB, Wester HJ. Synthesis and preclinical

characterization of the PSMA-targeted hybrid tracer PSMA-I&F for nuclear and fluorescence imaging of prostate cancer. *J Nucl Med.* 2018 Sep 20. pii: jnumed.118.212720. doi: 10.2967/jnumed.118.212720.

311. Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castaño JP, Wester HJ, Culler M, Melmed S, Schulz S. International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. *Pharmacol Rev.* 2018 Oct;70(4):763-835.
310. Soldatov A, von Klot CAJ, Walacides D, Derlin T, Bengel FM, Ross TL, Wester HJ, Derlin K, Kuczyk MA, Christiansen H, Henkenberens C. Patterns of progression after (68)Ga-PSMA-ligand PET/CT-guided radiotherapy for recurrent prostate cancer. *Int J Radiat Oncol Biol Phys.* 2018 Sep 7. pii: S0360-3016(18)33708-8.
309. Vag T, Steiger K, Rossmann A, Keller U, Noske A, Herhaus P, Ettl J, Niemeyer M, Wester HJ, Schwaiger M. PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma. *EJNMMI Res.* 2018 Sep 6;8(1):90.
308. Cytawa W, Kircher S, Schirbel A, Shirai T, Fukushima K, Buck AK, Wester HJ, Lapa C. Chemokine Receptor 4 Expression in Primary Sjögren's Syndrome. *Clin Nucl Med.* 2018 Nov;43(11):835-836.
307. Wirtz M, Schmidt A, Schottelius M, Robu S, Günther T, Schwaiger M, Wester HJ. Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity. *EJNMMI Res.* 2018 Aug 22;8(1):84.
306. Grimmer T, Shi K, Diehl-Schmid J, Natale B, Drzezga A, Förster S, Förstl H, Schwaiger M, Yakushev I, Wester HJ, Kurz A, Yousefi BH. (18)F-FIBT may expand PET for β -amyloid imaging in neurodegenerative diseases. *Mol Psychiatry.* 2018 Aug 17. doi: 10.1038/s41380-018-0203-5.
305. Kircher M, Herhaus P, Schottelius M, Buck AK, Werner RA, Wester HJ, Keller U, Lapa C. CXCR4-directed theranostics in oncology and inflammation. *Ann Nucl Med.* 2018 Oct;32(8):503-511. doi: 10.1007/s12149-018-1290-8. Epub 2018 Aug 13. Review.
304. Šimeček J, Hermann P, Seidl C, Bruchertseifer F, Morgenstern A, Wester HJ, Notni J. Efficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: towards improved alpha-therapeutics. *EJNMMI Res.* 2018 Aug 8;8(1):78. doi: 10.1186/s13550-018-0431-3.
303. Schmidt A, Wirtz M, Färber SF, Osl T, Beck R, Schottelius M, Schwaiger M, Wester HJ. Effect of Carbohydration on the Theranostic Tracer PSMA I&T. *ACS Omega.* 2018 Jul 31;3(7):8278-8287.
302. Färber SF, Wurzer A, Reichart F, Beck R, Kessler H, Wester HJ, Notni J. Therapeutic Radiopharmaceuticals Targeting Integrin $\alpha\beta 6$. *ACS Omega.* 2018 Feb 28;3(2):2428-2436.
301. Wurzer A, Pollmann J, Schmidt A, Reich D, Wester HJ, Notni J. Molar Activity of Ga-68 Labeled PSMA Inhibitor Conjugates Determines PET Imaging Results. *Mol Pharm.* 2018 Sep 4;15(9):4296-4302.
300. Grosse GM, Bascuñana P, Schulz-Schaeffer WJ, Teebken OE, Wilhelmi M, Worthmann H, Ross TL, Wester HJ, Kropf S, Derlin T, Bengel FM, Bankstahl JP, Weissenborn K. Targeting Chemokine Receptor CXCR4 and Translocator Protein for Characterization of High-Risk Plaque in Carotid Stenosis Ex Vivo. *Stroke.* 2018 Aug;49(8):1988-1991.
299. Derlin T, Sedding DG, Dutzmann J, Haghikia A, König T, Napp LC, Schütze C, Owsianski-Hille N, Wester HJ, Kropf S, Thackeray JT, Bankstahl JP, Geworski L, Ross TL, Bauersachs J, Bengel FM. Imaging of chemokine receptor CXCR4 expression in culprit and nonculprit coronary atherosclerotic plaque using motion-corrected [(68)Ga]pentixafor PET/CT. *Eur J Nucl Med Mol Imaging.* 2018 Oct;45(11):1934-1944.
298. Li X, Kemmer L, Zhang X, Kircher M, Buck AK, Wester HJ, Hacker M, Lapa C. Anti-Inflammatory Effects on Atherosclerotic Lesions Induced by CXCR4-Directed Endoradiotherapy. *J Am Coll Cardiol.* 2018 Jul 3;72(1):122-123.
297. Vágner A, Forgács A, Brücher E, Tóth I, Maiocchi A, Wurzer A, Wester HJ, Notni J, Baranyai Z. Equilibrium Thermodynamics, Formation, and Dissociation Kinetics of Trivalent Iron and Gallium Complexes of Triazacyclononane-Triphosphinate (TRAP) Chelators: Unraveling the Foundations of Highly Selective Ga-68 Labeling. *Front Chem.* 2018 May 23;6:170. doi: 10.3389/fchem.2018.00170.
296. Lapa C, Hänscheid H, Kircher M, Schirbel A, Wunderlich G, Werner R, Samnick S, Kotzerke J, Einsele H, Buck A, Wester HJ, Grigoleit GU. Feasibility of CXCR4-directed radioligand therapy in advanced diffuse large B cell lymphoma. *J Nucl Med.* 2018 May 18. pii: jnumed.118.210997.

295. Kletting P, Thieme A, Eberhardt N, Rinscheid A, D'Alessandria C, Allmann J, Wester HJ, Tauber R, Beer AJ, Glatting G, Eiber M. Modeling and predicting tumor response in radioligand therapy. *J Nucl Med*. 2018 May 10. pii: jnumed.118.210377. doi: 10.2967/jnumed.118.210377.
294. Lücke F, Blazquez R, Yamaci RF, Lu X, Pregler B, Hannus S, Menhart K, Hellwig D, Wester HJ, Kropf S, Heudobler D, Grosse J, Moosbauer J, Hutterer M, Hau P, Riemenschneider MJ, Bayerlová M, Bleckmann A, Polzer B, Beißbarth T, Klein CA, Pukrop T. Isolated metastasis of an EGFR-L858R-mutated NSCLC of the meninges: the potential impact of CXCL12/CXCR4 axis in EGFR(mut) NSCLC in diagnosis, follow-up and treatment. *Oncotarget*. 2018 Apr 10;9(27):18844-18857.
293. Wurzer A, Vágner A, Horváth D, Fellegi F, Wester HJ, Kálmán FK, Notni J. Synthesis of Symmetrical Tetrameric Conjugates of the Radiolanthanide Chelator DOTPI for Application in Endoradiotherapy by Means of Click Chemistry. *Front Chem*. 2018 Apr 10;6:107. doi: 10.3389/fchem.2018.00107. eCollection 2018.
292. Di Leva FS, Tomassi S, Di Maro S, Reichart F, Notni J, Dangi A, Marelli UK, Brancaccio D, Merlino F, Wester HJ, Novellino E, Kessler H, Marinelli L. From a Helix to a Small Cycle: Metadynamics-Inspired $\alpha\beta$ 6 Integrin Selective Ligands. *Angew Chem Int Ed Engl*. 2018 Oct 26;57(44):14645-14649.
291. Robu S, Schmidt A, Eiber M, Schottelius M, Günther T, Hooshyar Yousefi B, Schwaiger M, Wester HJ. Synthesis and preclinical evaluation of novel (18)F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with (18)F-DCFPyl and (18)F-PSMA-1007. *EJNMMI Res*. 2018 Apr 12;8(1):30. doi: 10.1186/s13550-018-0382-8.
290. Mayerhoefer ME, Jaeger U, Staber P, Raderer M, Wadsak W, Pfaff S, Kornauth C, Senn D, Weber M, Wester HJ, Skrabbs C, Haug A. [68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia: Preliminary Results. *Invest Radiol*. 2018 Jul;53(7):403-408. doi: 10.1097/RLI.0000000000000469.
289. Lobeek D, Franssen GM, Ma MT, Wester HJ, Decristoforo C, Oyen WJG, Boerman OC, Terry SYA, Rijpkema M. In Vivo Characterization of 4 (68)Ga-Labeled Multimeric RGD Peptides to Image $\alpha(v)\beta(3)$ Integrin Expression in 2 Human Tumor Xenograft Mouse Models. *J Nucl Med*. 2018 Aug;59(8):1296-1301.
287. Maurer T, Robu S, Schottelius M, Schwamborn K, Rauscher I, van den Berg NS, van Leeuwen FWB, Haller B, Horn T, Heck MM, Gschwend JE, Schwaiger M, Wester HJ, Eiber M. (99m)Technetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer. *Eur Urol*. 2018 Apr 3. pii: S0302-2838(18)30189-1. doi: 10.1016/j.eururo.2018.03.013.
286. Derlin T, Grünwald V, Steinbach J, Wester HJ, Ross TL. Molecular Imaging in Oncology Using Positron Emission Tomography. *Dtsch Arztebl Int*. 2018 Mar 16;115(11):175-181. doi: 10.3238/arztebl.2018.0175.
285. Kapp TG, Di Leva FS, Notni J, Räder AFB, Fottner M, Reichart F, Reich D, Wurzer A, Steiger K, Novellino E, Marelli UK, Wester HJ, Marinelli L, Kessler H. N-Methylation of isoDGR Peptides: Discovery of a Selective $\alpha 5\beta 1$ -Integrin Ligand as a Potent Tumor Imaging Agent. *J Med Chem*. 2018 Mar 22;61(6):2490-2499.
284. Reiter T, Kircher M, Schirbel A, Werner RA, Kropf S, Ertl G, Buck AK, Wester HJ, Bauer WR, Lapa C. Imaging of C-X-C Motif Chemokine Receptor CXCR4 Expression After Myocardial Infarction With [(68)Ga]Pentixafor-PET/CT in Correlation With Cardiac MRI. *JACC Cardiovasc Imaging*. 2018 Oct;11(10):1541-1543.
283. Lapa C, Lücknerath K, Kircher S, Hänscheid H, Grigoleit GU, Rosenwald A, Stolzenburg A, Kropf S, Einsele H, Wester HJ, Buck AK, Kortüm KM, Schirbel A. Potential influence of concomitant chemotherapy on CXCR4 expression in receptor directed endoradiotherapy. *Br J Haematol*. 2018 Jan 24. doi: 10.1111/bjh.15096.
282. Derlin T, Schmuck S, Juhl C, Teichert S, Zörgiebel J, Wester HJ, Schneefeld SM, Walte ACA, Thackeray JT, Ross TL, Bengel FM. Imaging Characteristics and First Experience of [(68)Ga]THP-PSMA, a Novel Probe for Rapid Kit-Based Ga-68 Labeling and PET Imaging: Comparative Analysis with [(68)Ga]PSMA I&T. *Mol Imaging Biol*. 2018 Aug;20(4):650-658. doi: 10.1007/s11307-018-1160-8.
281. Koenig T, Sedding DG, Wester HJ, Derlin T. Seeing the unseen: post-infarction inflammation in an isolated right ventricular myocardial infarction visualized by combined cardiac magnetic resonance imaging and chemokine receptor CXCR4-targeted molecular imaging. *Eur Heart J*. 2018 Mar 14;39(11):966.
280. Habringer S, Lapa C, Herhaus P, Schottelius M, Istvanffy R, Steiger K, Slotta-Huspenina J, Schirbel A, Hänscheid H, Kircher S, Buck AK, Götze K, Vick B, Jeremias I, Schwaiger M, Peschel C, Oostendorp R, Wester HJ, Grigoleit GU, Keller U. Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics. *Theranostics*. 2018 Jan 1;8(2):369-383. doi: 10.7150/thno.21397. eCollection 2018. PubMed

279. Heinze B, Fuss CT, Mulatero P, Beuschlein F, Reincke M, Mustafa M, Schirbel A, Deutschbein T, Williams TA, Rhayem Y, Quinkler M, Rayes N, Monticone S, Wild V, Gomez-Sanchez CE, Reis AC, Petersenn S, Wester HJ, Kropf S, Fassnacht M, Lang K, Herrmann K, Buck AK, Bluemel C, Hahner S. Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. *Hypertension*. 2018 Feb;71(2):317-325. doi: 10.1161/HYPERTENSIONAHA.117.09975.
278. von Klot CJ, Merseburger AS, Böker A, Schmuck S, Ross TL, Bengel FM, Kuczyk MA, Henkenberens C, Christiansen H, Wester HJ, Solass W, Lafos M, Derlin T. (68)Ga-PSMA PET/CT Imaging Predicting Intraprostatic Tumor Extent, Extracapsular Extension and Seminal Vesicle Invasion Prior to Radical Prostatectomy in Patients with Prostate Cancer. *Nucl Med Mol Imaging*. 2017 Dec;51(4):314-322. doi:10.1007/s13139-017-0476-7.
277. Lapa C, Kircher S, Schirbel A, Rosenwald A, Kropf S, Pelzer T, Walles T, Buck AK, Weber WA, Wester HJ, Herrmann K, Lückerrath K. Targeting CXCR4 with [(68)Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma? *Oncotarget*. 2017 May 27;8(57):96732-96737. doi: 10.18632/oncotarget.18235. eCollection 2017
276. Schwarzenböck SM, Stenzel J, Otto T, Helldorff HV, Bergner C, Kurth J, Polei S, Lindner T, Rauer R, Hohn A, Hakenberg OW, Wester HJ, Vollmar B, Krause BJ. [(68)Ga]pentixafor for CXCR4 imaging in a PC-3 prostate cancer xenograft model - comparison with [(18)F]FDG PET/CT, MRI and ex vivo receptor expression. *Oncotarget*. 2017 Sep 16;8(56):95606-95619. doi: 10.18632/oncotarget.21024. eCollection 2017
275. Fang HY, Münch NS, Schottelius M, Ingermann J, Liu H, Schauer M, Stangl S, Multhoff G, Steiger K, Gerngroß C, Jesinghaus M, Weichert W, Kühl AA, Sepulveda AR, Wester HJ, Wang TC, Quante M. CXCR4 Is a Potential Target for Diagnostic PET/CT Imaging in Barrett's Dysplasia and Esophageal Adenocarcinoma. *Clin Cancer Res*. 2018 Mar 1;24(5):1048-1061. doi: 10.1158/1078-0432.CCR-17-1756.
274. Notni J, Wester HJ. Re-thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals. *J Labelled Comp Radiopharm*. 2018 Mar;61(3):141-153. doi: 10.1002/jlcr.3582.
273. Henkenberens C, Derlin T, Bengel FM, Ross TL, Wester HJ, Hueper K, Kuczyk MA, Christiansen H, von Klot CA. Patterns of relapse as determined by (68)Ga-PSMA ligand PET/CT after radical prostatectomy : Importance for tailoring and individualizing treatment. *Strahlenther Onkol*. 2018 Apr;194(4):303-310. doi: 10.1007/s00066-017-1231-9.
272. Wacker A, Carniato F, Platas-Iglesias C, Esteban-Gomez D, Wester HJ, Tei L, Notni J. Dimer formation of GdDO3A-arylsulfonamide complexes causes loss of pH-dependency of relaxivity. *Dalton Trans*. 2017 Dec 12;46(48):16828-16836. doi: 10.1039/c7dt02985c.
272. Li X, Heber D, Leike T, Beitzke D, Lu X, Zhang X, Wei Y, Mitterhauser M, Wadsak W, Kropf S, Wester HJ, Loewe C, Hacker M, Haug AR. [68Ga]Pentixafor-PET/MRI for the detection of Chemokine receptor 4 expression in atherosclerotic plaques. *Eur J Nucl Med Mol Imaging*. 2018 Apr;45(4):558-566. doi: 10.1007/s00259-017-3831-0.
271. Buck AK, Stolzenburg A, Hänscheid H, Schirbel A, Lückerrath K, Schottelius M, Wester HJ, Lapa C. Chemokine receptor - Directed imaging and therapy. *Methods*. 2017 Nov 1;130:63-71. doi: 10.1016/j.ymeth.2017.09.002. Epub 2017 Sep 12. Review.
270. Nieberler M, Reuning U, Reichart F, Notni J, Wester HJ, Schwaiger M, Weinmüller M, Räder A, Steiger K, Kessler H. Exploring the Role of RGD-Recognizing Integrins in Cancer. *Cancers (Basel)*. 2017 Sep 4;9(9). pii: E116. doi: 10.3390/cancers9090116.
269. Walenkamp AME, Lapa C, Herrmann K, Wester HJ. CXCR4 Ligands: The Next Big Hit? *J Nucl Med*. 2017 Sep;58(Suppl 2):77S-82S. doi: 10.2967/jnumed.116.186874. Review.
268. Wurzer A, Seidl C, Morgenstern A, Bruchertseifer F, Schwaiger M, Wester HJ, Notni J. Dual-Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in Radiotherapy. *Chemistry*. 2018 Jan 12;24(3):547-550. doi: 10.1002/chem.201702335.
267. Vidal-Sicart S, Valdés Olmos R, Nieweg OE, Faccini R, Grootendorst MR, Wester HJ, Navab N, Vojnovic B, van der Poel H, Martínez-Román S, Klode J, Wawroschek F, van Leeuwen FWB. From interventionist imaging to intraoperative guidance: New perspectives by combining advanced tools and navigation with radio-guided surgery. *Rev Esp Med Nucl Imagen Mol*. 2018 Jan - Feb;37(1):28-40. doi: 10.1016/j.remnm.2017.06.004.
266. Weiberg D, Thackeray JT, Daum G, Sohns JM, Kropf S, Wester HJ, Ross TL, Bengel FM, Derlin T. Clinical Molecular Imaging of Chemokine Receptor CXCR4 Expression in Atherosclerotic Plaque Using (68)Ga-

Pentixafor PET: Correlation with Cardiovascular Risk Factors and Calcified Plaque Burden. *J Nucl Med.* 2018 Feb;59(2):266-272.

265. Schottelius M, Osl T, Poschenrieder A, Hoffmann F, Beykan S, Hänscheid H, Schirbel A, Buck AK, Kropf S, Schwaiger M, Keller U, Lassmann M, Wester HJ. [(177)Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent. *Theranostics.* 2017 Jun 11;7(9):2350-2362. doi: 10.7150/thno.19119. eCollection 2017.
264. Bouter C, Meller B, Sahlmann CO, Staab W, Wester HJ, Kropf S, Meller J. (68)Ga-Pentixafor PET/CT Imaging of Chemokine Receptor CXCR4 in Chronic Infection of the Bone: First Insights. *J Nucl Med.* 2018 Feb;59(2):320-326. doi: 10.2967/jnumed.117.193854.
263. Knorr K, Eiber M, Maurer T, Wester HJ, Scheidhauer K. [PET-CT and PET-MRI of the prostate : From (18)F-FDG to (68)Ga-PSMA]. *Radiologe.* 2017 Aug;57(8):631-636. doi: 10.1007/s00117-017-0276-1. Review.
262. Steiger K, Schlitter AM, Weichert W, Esposito I, Wester HJ, Notni J. Perspective of $\alpha\beta 6$ -Integrin Imaging for Clinical Management of Pancreatic Carcinoma and Its Precursor Lesions. *Mol Imaging.* 2017 Jan 1;16:1536012117709384. doi: 10.1177/1536012117709384.
261. Herhaus P, Habringer S, Vag T, Steiger K, Slotta-Huspenina J, Gerngroß C, Wiestler B, Wester HJ, Schwaiger M, Keller U. Response assessment with the CXCR4-directed positron emission tomography tracer [(68)Ga]Pentixafor in a patient with extranodal marginal zone lymphoma of the orbital cavities. *EJNMMI Res.* 2017 Dec;7(1):51. doi: 10.1186/s13550-017-0294-z.
260. Lapa C, Herrmann K, Schirbel A, Hänscheid H, Lücknerath K, Schottelius M, Kircher M, Werner RA, Schreder M, Samnick S, Kropf S, Knop S, Buck AK, Einsele H, Wester HJ, Kortüm KM. CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma. *Theranostics.* 2017 Apr 8;7(6):1589-1597. doi: 10.7150/thno.19050. eCollection 2017.
259. Werner RA, Weich A, Higuchi T, Schmid JS, Schirbel A, Lassmann M, Wild V, Rudelius M, Kudlich T, Herrmann K, Scheurlen M, Buck AK, Kropf S, Wester HJ, Lapa C. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach. *Theranostics.* 2017 Apr 5;7(6):1489-1498. doi:10.7150/thno.18754. eCollection 2017.
258. Schmuck S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, Ross TL, Bengel FM, Derlin T. Initial Experience with Volumetric (68)Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer. *J Nucl Med.* 2017 Dec;58(12):1962-1968. doi: 10.2967/jnumed.117.193581.
257. Derlin T, Gueler F, Bräsen JH, Schmitz J, Hartung D, Herrmann TR, Ross TL, Wacker F, Wester HJ, Hiss M, Haller H, Bengel FM, Hueper K. Integrating MRI and Chemokine Receptor CXCR4-Targeted PET for Detection of Leukocyte Infiltration in Complicated Urinary Tract Infections After Kidney Transplantation. *J Nucl Med.* 2017 Nov;58(11):1831-1837. doi: 10.2967/jnumed.117.193037.
256. Keller M, Maschauer S, Brennauer A, Tripal P, Koglin N, Dittrich R, Bernhardt G, Kuwert T, Wester HJ, Buschauer A, Prante O. Prototypic (18)F-Labeled Argininamide-Type Neuropeptide Y Y(1)R Antagonists as Tracers for PET Imaging of Mammary Carcinoma. *ACS Med Chem Lett.* 2017 Feb 21;8(3):304-309. doi: 10.1021/acsmchemlett.6b00467. eCollection 2017 Mar 9. PubMed PMID: 28337321;
255. Henkenberens C, VON Klot CA, Ross TL, Bengel FM, Wester HJ, Katja H, Christiansen H, Derlin T. (68)Ga-PSMA Ligand PET/CT-based Radiotherapy for Lymph Node Relapse of Prostate Cancer After Primary Therapy Delays Initiation of Systemic Therapy. *Anticancer Res.* 2017 Mar;37(3):1273-1279.
254. Nonnekens J, Chatalic KL, Molkenboer-Kuening JD, Beerens CE, Bruchertseifer F, Morgenstern A, Veldhoven-Zweistra J, Schottelius M, Wester HJ, van Gent DC, van Weerden WM, Boerman OC, de Jong M, Heskamp S. (213)Bi-Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-Strand Breaks in Prostate Cancer Xenografts. *Cancer Biother Radiopharm.* 2017 Mar;32(2):67-73.
253. Maschauer S, Einsiedel J, Reich D, Hübner H, Gmeiner P, Wester HJ, Prante O, Notni J. Theranostic Value of Multimers: Lessons Learned from Trimerization of Neurotensin Receptor Ligands and Other Targeting Vectors. *Pharmaceuticals (Basel).* 2017 Mar 10;10(1). pii: E29. doi: 10.3390/ph10010029.
252. Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, Giesel F, Haberkorn U, Hope TA, Kopka K, Krause BJ, Mottaghy FM, Schöder H, Sunderland J, Wan S, Wester HJ, Fanti S, Herrmann K. (68)Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. *Eur J Nucl Med Mol Imaging.* 2017 Jun;44(6):1014-1024. doi: 10.1007/s00259-017-3670-z.

251. Schmuck S, Nordlohne S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, Ross TL, Bengel FM, Derlin T. Comparison of standard and delayed imaging to improve the detection rate of [(68)Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer. *Eur J Nucl Med Mol Imaging*. 2017 Jun;44(6):960-968.
250. Lapa C, Schirbel A, Samnick S, Lückerrath K, Kortüm KM, Knop S, Wester HJ, Buck AK, Schreder M. The gross picture: intraindividual tumour heterogeneity in a patient with nonsecretory multiple myeloma. *Eur J Nucl Med Mol Imaging*. 2017 Jun;44(6):1097-1098. doi: 10.1007/s00259-017-3656-x.
249. Schmuck S, Mamach M, Wilke F, von Klot CA, Henkenberens C, Thackeray JT, Sohns JM, Geworski L, Ross TL, Wester HJ, Christiansen H, Bengel FM, Derlin T. Multiple Time-Point 68Ga-PSMA I&T PET/CT for Characterization of Primary Prostate Cancer: Value of Early Dynamic and Delayed Imaging. *Clin Nucl Med*. 2017 Jun;42(6):e286-e293. doi: 10.1097/RLU.0000000000001589.
248. Einspieler I, Rauscher I, Düwel C, Krönke M, Rischpler C, Habl G, Dewes S, Ott A, Wester HJ, Schwaiger M, Maurer T, Eiber M. Detection Efficacy of Hybrid (68)Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria. *J Nucl Med*. 2017 Jul;58(7):1081-1087. doi: 10.2967/jnumed.116.184457.
247. Derlin T, Wester HJ, Bengel FM, Hueper K. Visualization of Posttraumatic Splenosis on Chemokine Receptor CXCR4-Targeted PET/CT. *Clin Nucl Med*. 2017 Jun;42(6):e317-e318. doi: 10.1097/RLU.0000000000001590. PubMed PMID: 28195912.
246. Reich D, Wurzer A, Wirtz M, Stiegler V, Spatz P, Pollmann J, Wester HJ, Notni J. Dendritic poly-chelator frameworks for multimeric bioconjugation. *Chem Commun (Camb)*. 2017 Feb 23;53(17):2586-2589. doi: 10.1039/c6cc10169k.
245. Brogsitter C, Hartmann H, Wunderlich G, Schottelius M, Wester HJ, Kotzerke J. Twins in spirit part IV - [(177)Lu] high affinity DOTATATE. A promising new tracer for peptide receptor radiotherapy? *Nuklearmedizin*. 2017 Feb 14;56(1):1-8. doi: 10.3413/Nukmed-0860-16-11. Epub 2017 Jan 31. PubMed PMID: 28138688.
244. Watts A, Singh B, Basher R, Singh H, Bal A, Kapoor R, Arora SK, Wester HJ, Mittal BR, Behera D. 68Ga-Pentixafor PET/CT demonstrating higher CXCR4 density in small cell lung carcinoma than in non-small cell variant. *Eur J Nucl Med Mol Imaging*. 2017 May;44(5):909-910. doi: 10.1007/s00259-017-3622-7.
243. Kapp TG, Rechenmacher F, Neubauer S, Maltsev OV, Cavalcanti-Adam EA, Zarka R, Reuning U, Notni J, Wester HJ, Mas-Moruno C, Spatz J, Geiger B, Kessler H. A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins. *Sci Rep*. 2017 Jan 11;7:39805. doi: 10.1038/srep39805.
242. Lapa C, Schreder M, Schirbel A, Samnick S, Kortüm KM, Herrmann K, Kropf S, Einsele H, Buck AK, Wester HJ, Knop S, Lückerrath K. [(68)Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma – Comparison to [(18)F]FDG and laboratory values. *Theranostics*. 2017 Jan 1;7(1):205-212. doi: 10.7150/thno.16576. eCollection 2017.
241. Poschenrieder A, Schottelius M, Osl T, Schwaiger M, Wester HJ. [(64)Cu]NOTA-pentixather enables high resolution PET imaging of CXCR4 expression in a preclinical lymphoma model. *EJNMMI Radiopharm Chem*. 2017;2(1):2. doi: 10.1186/s41181-016-0020-6. Epub 2017 Jan 19. PubMed PMID: 29527563; PubMed Central PMCID: PMC5835975.
240. Kazmierczak PM, Todica A, Gildehaus FJ, Hirner-Eppeneder H, Brendel M, Eschbach RS, Hellmann M, Nikolaou K, Reiser MF, Wester HJ, Kropf S, Rominger A, Cyran CC. 68Ga-TRAP-(RGD)3 Hybrid Imaging for the In Vivo Monitoring of $\alpha\beta 3$ -Integrin Expression as Biomarker of Anti-Angiogenic Therapy Effects in Experimental Breast Cancer. *PLoS One*. 2016 Dec 19;11(12):e0168248. doi: 10.1371/journal.pone.0168248. eCollection 2016.
239. Notni J, Reich D, Maltsev OV, Kapp TG, Steiger K, Hoffmann F, Esposito I, Weichert W, Kessler H, Wester HJ. In Vivo PET Imaging of the Cancer Integrin $\alpha\beta 6$ Using (68)Ga-Labeled Cyclic RGD Nonapeptides. *J Nucl Med*. 2017 Apr;58(4):671-677. doi: 10.2967/jnumed.116.182824.
238. Berliner C, Tienken M, Frenzel T, Kobayashi Y, Helberg A, Kirchner U, Klutmann S, Beyersdorff D, Budäus L, Wester HJ, Mester J, Bannas P. Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [(68)Ga]PSMA I&T and comparison with published data of [(68)Ga]PSMA HBED-CC. *Eur J Nucl Med Mol Imaging*. 2016 Nov 28. [Epub ahead of print] PubMed PMID: 27896369.

237. Rauscher I, Düwel C, Wirtz M, Schottelius M, Wester HJ, Schwamborn K, Haller B, Schwaiger M, Gschwend JE, Eiber M, Maurer T. Value of (111) In-PSMA-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up. *BJU Int*. 2016 Nov 10. doi: 10.1111/bju.13713. [Epub ahead of print] PubMed PMID: 27862863.
236. Werner RA, Weich A, Schirbel A, Samnick S, Buck AK, Higuchi T, Wester HJ, Lapa C. Intraindividual tumor heterogeneity in NET - Further insight by C-X-C motif chemokine receptor 4-directed Imaging. *Eur J Nucl Med Mol Imaging*. 2016 Nov 9.[Epub ahead of print] PubMed PMID: 27830282.
235. Bluemel C, Hahner S, Heinze B, Fassnacht M, Kroiss M, Bley TA, Wester HJ, Kropf S, Lapa C, Schirbel A, Buck AK, Herrmann K. Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients. *Clin Nucl Med*. 2016 Nov 4. [Epub ahead of print] PubMed PMID: 27819856.
234. Hyafil F, Pelisek J, Laitinen I, Schottelius M, Mohring M, Döring Y, Van der Vorst E, Kallmayer M, Steiger K, Poschenrieder A, Notni J, Fischer J, Baumgartner C, Rischpler C, Nekolla S, Weber C, Eckstein HH, Wester HJ, Schwaiger M. Imaging the cytokine receptor CXCR4 in atherosclerotic plaques with the radiotracer 68Ga-pentixafor for positron emission tomography. *J Nucl Med*. 2016 Oct 27. pii:jnumed.116.179663. [Epub ahead of print] PubMed PMID: 27789718.
232. Bluemel C, Linke F, Herrmann K, Simunovic I, Eiber M, Kestler C, Buck AK, Schirbel A, Bley TA, Wester HJ, Vergho D, Becker A. Impact of (68)Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy. *EJNMMI Res*. 2016 Dec;6(1):78. PubMed PMID: 27785766; PubMed Central PMCID: PMC5081978.
231. Derlin T, Thiele J, Weiberg D, Thackeray JT, Püschel K, Wester HJ, Aguirre Dávila L, Larena-Avellaneda A, Daum G, Bengel FM, Schumacher U. Evaluation of 68Ga-Glutamate Carboxypeptidase II Ligand Positron Emission Tomography for Clinical Molecular Imaging of Atherosclerotic Plaque Neovascularization. *Arterioscler Thromb Vasc Biol*. 2016 Nov;36(11):2213-2219. PubMed PMID: 27609368.
230. Kulkarni HR, Singh A, Schuchardt C, Niepsch K, Sayeg M, Leshch Y, Wester HJ, Baum RP. PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013. *J Nucl Med*. 2016 Oct;57(Suppl 3):97S-104S. PubMed PMID: 27694180.
229. Okamoto S, Thieme A, Allmann J, D'Alessandria C, Maurer T, Retz M, Tauber R, Heck MM, Wester HJ, Tamaki N, Fendler WP, Herrmann K, Pfob CH, Scheidhauer K, Schwaiger M, Ziegler S, Eiber M. Radiation dosimetry for 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: Absorbed dose in normal organs and tumor lesions. *J Nucl Med*. 2016 Sep 22. pii: jnumed.116.178483. [Epub ahead of print] PubMed PMID: 27660138.
228. Poschenrieder A, Schottelius M, Schwaiger M, Wester HJ. Preclinical evaluation of [(68)Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo - a comparison to [(68)Ga]pentixafor. *EJNMMI Res*. 2016 Dec;6(1):70. doi: 10.1186/s13550-016-0227-2. PubMed PMID: 27655427; PubMed Central PMCID: PMC5031577.
227. Robu S, Schottelius M, Eiber M, Maurer T, Gschwend J, Schwaiger M, Wester HJ. Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer. *J Nucl Med*. 2016 Sep 15. pii: jnumed.116.178939. [Epub ahead of print] PubMed PMID: 27635024.
226. Schmid JS, Schirbel A, Buck AK, Kropf S, Wester HJ, Lapa C. [68Ga]Pentixafor-Positron Emission Tomography/Computed Tomography Detects Chemokine Receptor CXCR4 Expression After Ischemic Stroke. *Circ Cardiovasc Imaging*. 2016 Sep;9(9):e005217. doi: 10.1161/CIRCIMAGING.116.005217. PubMed PMID: 27613700.
225. Mendler CT, Feuchtinger A, Heid I, Aichler M, D'Alessandria C, Pirsig S, Blechert B, Wester HJ, Braren R, Walch A, Skerra A, Schwaiger M. Tumor Uptake of Anti-CD20 Fabs Depends on Tumor Perfusion. *J Nucl Med*. 2016 Dec;57(12):1971-1977. PubMed PMID: 27417649.
224. Notni J, Wester HJ. A Practical Guide on the Synthesis of Metal Chelates for Molecular Imaging and Therapy by Means of Click Chemistry. *Chemistry*. 2016 Aug 8;22(33):11500-8. doi: 10.1002/chem.201600928. Review. PubMed PMID: 27333118.
223. Maurer T, Schwamborn K, Schottelius M, Wester HJ, Schwaiger M, Gschwend JE, Eiber M. PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer. *Clin Genitourin Cancer*. 2016 Oct;14(5):e549-e552. doi: 10.1016/j.clgc.2016.05.020. PubMed PMID: 27318956.
222. Rauscher I, Maurer T, Souvatzoglou M, Beer AJ, Vag T, Wirtz M, Weirich G, Wester HJ, Gschwend JE, Schwaiger M, Schottelius M, Eiber M. Inpatient Comparison of 111In-PSMA I&T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer. *Clin Nucl Med*. 2016 Sep;41(9):e397-402. doi: 10.1097/RLU.0000000000001273. PubMed PMID: 27276206.
221. Henkenberens C, von Klot CA, Ross TL, Bengel FM, Wester HJ, Merseburger AS, Vogel-Claussen J, Christiansen H, Derlin T. (68)Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer :Early efficacy after primary therapy. *Strahlenther Onkol*. 2016 Jul;192(7):431-9. doi: 10.1007/s00066-016-0982-z. PubMed PMID: 27272755.
220. Pfob CH, Ziegler S, Graner FP, Köhner M, Schachoff S, Blechert B, Wester HJ, Scheidhauer K, Schwaiger M, Maurer T, Eiber M. Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer. *Eur J Nucl Med Mol Imaging*. 2016 Oct;43(11):1962-70. doi:10.1007/s00259-016-3424-3. PubMed PMID: 27207281.
219. Herhaus P, Habringer S, Philipp-Abbrederis K, Vag T, Gerngross C, Schottelius M, Slotta-Huspenina J, Steiger K, Altmann T, Weißer T, Steidle S, Schick M, Jacobs L, Slawska J, Müller-Thomas C, Verbeek M, Subklewe M, Peschel C, Wester HJ, Schwaiger M, Götze K, Keller U. Targeted positron emission tomography

- imaging of CXCR4 expression in patients with acute myeloid leukemia. *Haematologica*. 2016 Aug;101(8):932-40. doi: 10.3324/haematol.2016.142976. PubMed PMID: 27175029; PubMed Central PMCID: PMC4967572.
218. Chatalic KL, Heskamp S, Konijnenberg M, Molkenboer-Kuening JD, Franssen GM, Clahsen-van Groningen MC, Schottelius M, Wester HJ, van Weerden WM, Boerman OC, de Jong M. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent. *Theranostics*. 2016 Apr 12;6(6):849-61. doi: 10.7150/thno.14744. PubMed PMID: 27162555; PubMed Central PMCID: PMC4860893.
 217. Notni J, Steiger K, Hoffmann F, Reich D, Schwaiger M, Kessler H, Wester HJ. Variation of Specific Activities of ⁶⁸Ga-Aquibepirin and ⁶⁸Ga-Avebetrin Enables Selective PET Imaging of Different Expression Levels of Integrins $\alpha 5\beta 1$ and $\alpha v\beta 3$. *J Nucl Med*. 2016 Oct;57(10):1618-1624. PubMed PMID: 27151985.
 216. Poschenrieder A, Schottelius M, Schwaiger M, Kessler H, Wester HJ. The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity. *EJNMMI Res*. 2016 Dec;6(1):36. doi: 10.1186/s13550-016-0193-8. PubMed PMID: 27112767; PubMed Central PMCID: PMC4844575.
 215. Bunschoten A, van Willigen DM, Buckle T, van den Berg NS, Welling MM, Spa SJ, Wester HJ, van Leeuwen FW. Tailoring Fluorescent Dyes To Optimize a Hybrid RGD-Tracer. *Bioconjug Chem*. 2016 May 18;27(5):1253-8. doi: 10.1021/acs.bioconjchem.6b00093. PubMed PMID: 27074375.
 214. Beer AJ, Schwarzenböck SM, Zantl N, Souvatzoglou M, Maurer T, Watzlowik P, Kessler H, Wester HJ, Schwaiger M, Krause BJ. Non-invasive assessment of inter-and inpatient variability of integrin expression in metastasized prostate cancer by PET. *Oncotarget*. 2016 May 10;7(19):28151-9. doi: 10.18632/oncotarget.8611. PubMed PMID: 27058620; PubMed Central PMCID: PMC5053716.
 213. KleinJan GH, Bunschoten A, van den Berg NS, Olmos RA, Klop WM, Horenblas S, van der Poel HG, Wester HJ, van Leeuwen FW. Fluorescence guided surgery and tracer-dose, fact or fiction? *Eur J Nucl Med Mol Imaging*. 2016 Sep;43(10):1857-67. doi: 10.1007/s00259-016-3372-y. PubMed PMID: 27020580; PubMed Central PMCID: PMC4969335.
 212. Derlin T, Weiberg D, von Klot C, Wester HJ, Henkenberens C, Ross TL, Christiansen H, Merseburger AS, Bengel FM. (⁶⁸Ga)-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. *Eur Radiol*. 2016 Dec;26(12):4345-4353. PubMed PMID: 27011373.
 211. Bluemel C, Krebs M, Polat B, Linke F, Eiber M, Samnick S, Lapa C, Lassmann M, Riedmiller H, Czernin J, Rubello D, Bley T, Kropf S, Wester HJ, Buck AK, Herrmann K. ⁶⁸Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative ¹⁸F-Choline-PET/CT. *Clin Nucl Med*. 2016 Jul;41(7):515-21. doi: 10.1097/RLU.0000000000001197. PubMed PMID: 26975008; PubMed Central PMCID: PMC5006491.
 210. Heck MM, Retz M, D'Alessandria C, Rauscher I, Scheidhauer K, Maurer T, Storz E, Janssen F, Schottelius M, Wester HJ, Gschwend JE, Schwaiger M, Tauber R, Eiber M. Systemic Radioligand Therapy with (¹⁷⁷Lu) Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. *J Urol*. 2016 Aug;196(2):382-91. doi:10.1016/j.juro.2016.02.2969. PubMed PMID: 26964917.
 209. Lapa C, Lücknerath K, Kleinlein I, Monoranu CM, Linsenmann T, Kessler AF, Rudelius M, Kropf S, Buck AK, Ernestus RI, Wester HJ, Lohr M, Herrmann K. (⁶⁸Ga)-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma. *Theranostics*. 2016 Jan 25;6(3):428-34. doi: 10.7150/thno.13986. PubMed PMID: 26909116; PubMed Central PMCID: PMC4737728.
 208. Lapa C, Lücknerath K, Rudelius M, Schmid JS, Schoene A, Schirbel A, Samnick S, Pelzer T, Buck AK, Kropf S, Wester HJ, Herrmann K. [⁶⁸Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer—initial experience. *Oncotarget*. 2016 Feb 23;7(8):9288-95. doi: 10.18632/oncotarget.7063. PubMed PMID: 26843617; PubMed Central PMCID: PMC4891040.
 207. Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, Beer AJ, Wester HJ, Gschwend J, Schwaiger M, Maurer T. Simultaneous (⁶⁸Ga)-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. *Eur Urol*. 2016 Jan 18. pii: S0302-2838(16)00011-7. doi: 10.1016/j.eururo.2015.12.053. [Epub ahead of print] PubMed PMID: 26795686.
 206. Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, Schottelius M, Mueller D, Klette I, Wester HJ. ¹⁷⁷Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. *J Nucl Med*. 2016 Jul;57(7):1006-13. doi:10.2967/jnumed.115.168443. PubMed PMID: 26795286.
 205. Vag T, Gerngross C, Herhaus P, Eiber M, Philipp-Abbrederis K, Graner FP, Ettl J, Keller U, Wester HJ, Schwaiger M. First Experience with Chemokine Receptor CXCR4-Targeted PET Imaging of Patients with Solid Cancers. *J Nucl Med*. 2016 May;57(5):741-6. doi: 10.2967/jnumed.115.161034. PubMed PMID: 26769866.
 204. Lapa C, Reiter T, Werner RA, Ertl G, Wester HJ, Buck AK, Bauer WR, Herrmann K. [⁶⁸Ga]Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression After Myocardial Infarction. *JACC Cardiovasc Imaging*. 2015 Dec;8(12):1466-8. doi:10.1016/j.jcmg.2015.09.007. PubMed PMID: 26699115.203. Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, Wester HJ, Heck M, Kübler H, Beer AJ, Schwaiger M, Eiber M. Diagnostic Efficacy of (⁶⁸Ga)Gallium-PSMA-PET compared to Conventional Imaging in Lymph Node Staging of 130 consecutive Patients with Intermediate to High-Risk Prostate Cancer. *J Urol*. 2015 Dec 9. pii: S0022-5347(15)05397-5. doi: 10.1016/j.juro.2015.12.025. [Epub ahead of print] PubMed PMID: 26682756.
 202. Rischpler C, Nekolla SG, Kossmann H, Dirschinger RJ, Schottelius M, Hyafil F, Wester HJ, Laugwitz KL, Schwaiger M. Upregulated myocardial CXCR4-expression after myocardial infarction assessed by

- simultaneous GA-68 pentixafor PET/MRI. *J Nucl Cardiol*. 2015 Dec 14. [Epub ahead of print] PubMed PMID: 26667813.
201. Notni J, Steiger K, Hoffmann F, Reich D, Kapp TL, Rechenmacher F, Neubauer S, Kessler H, Wester HJ. Complementary, Selective PET-Imaging of Integrin Subtypes $\alpha 5\beta 1$ and $\alpha v\beta 3$ Using Ga-68-Aquibepirin and Ga-68-Avebetrin. *J Nucl Med*. 2015 Dec 3. pii: jnumed.115.165720. [Epub ahead of print] PubMed PMID: 26635338.
 200. Schottelius M, Wirtz M, Eiber M, Maurer T, Wester HJ. [(111)In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery. *EJNMMI Res*. 2015 Dec;5(1):68.
 199. Thackeray JT, Derlin T, Haghikia A, Napp LC, Wang Y, Ross TL, Schäfer A, Tillmanns J, Wester HJ, Wollert KC, Bauersachs J, Bengel FM. Molecular Imaging of the Chemokine Receptor CXCR4 After Acute Myocardial Infarction. *JACC Cardiovasc Imaging*. 2015 Nov 5. pii: S1936-878X(15)00759-7. doi: 10.1016/j.jcmg.2015.09.008.
 198. Herrmann K, Schottelius M, Lapa C, Osl T, Poschenrieder A, Haenscheid H, Lueckerath K, Schreder M, Bluemel C, Knott M, Keller U, Schirbel A, Samnick S, Lassmann M, Kropf S, Buck A, Einsele H, Wester HJ, Knop S. First-in-man experience of CXCR4-directed endoradiotherapy with ^{177}Lu - and ^{90}Y -labelled pentixafor in advanced stage multiple myeloma with extensive intra- and extramedullary disease. *J Nucl Med*. 2015 Nov 12. pii: jnumed.115.167361.
 197. D'Alessandria C, Pohle K, Rechenmacher F, Neubauer S, Notni J, Wester HJ, Schwaiger M, Kessler H, Beer AJ. In vivo biokinetic and metabolic characterization of the (68)Ga-labelled $\alpha 5\beta 1$ -selective peptidomimetic FR366. *Eur J Nucl Med Mol Imaging*. 2015 Oct 24. [Epub ahead of print] PubMed PMID: 26497698.
 196. Schwarzenböck SM, Schmeja P, Kurth J, Souvatzoglou M, Nawroth R, Treiber U, Kundt G, Berndt S, Graham K, Senekowitsch-Schmidtke R, Schwaiger M, Ziegler SI, Dinkelborg L, Wester HJ, Krause BJ. Comparison of [(11)C]Choline [(11)C]CHO and [(18)F]Bombesin (BAY 86-4367) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model. *Mol Imaging Biol*. 2015 Oct 19. [Epub ahead of print] PubMed PMID: 26483088.
 195. Gempt J, Bette S, Buchmann N, Ryang YM, Förschler A, Pyka T, Wester HJ, Förster S, Meyer B, Ringel F. Volumetric Analysis of F-18-FET-PET Imaging for Brain Metastases. *World Neurosurg*. 2015 Dec;84(6):1790-7.
 194. Pyka T, Gempt J, Hiob D, Ringel F, Schlegel J, Bette S, Wester HJ, Meyer B, Förster S. Textural analysis of pre-therapeutic [18F]-FET-PET and its correlation with tumor grade and patient survival in high-grade gliomas. *Eur J Nucl Med Mol Imaging*. 2016 Jan;43(1):133-41.
 193. Máté G, Šimeček J, Pniok M, Kertész I, Notni J, Wester HJ, Galuska L, Hermann P. The influence of the combination of carboxylate and phosphinate pendant arms in 1,4,7-triazacyclononane-based chelators on their ^{68}Ga labelling properties. *Molecules*. 2015 Jul 21;20(7):13112-26.
 192. Metz S, Ganter C, Lorenzen S, van Marwick S, Holzapfel K, Herrmann K, Rummeny EJ, Wester HJ, Schwaiger M, Nekolla SG, Beer AJ. Multiparametric MR and PET Imaging of Intratumoral Biological Heterogeneity in Patients with Metastatic Lung Cancer Using Voxel-by-Voxel Analysis. *PLoS One*. 2015 Jul 17;10(7):e0132386.
 191. Weineisen M, Simecek J, Schottelius M, Schwaiger M, Wester HJ. Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. *EJNMMI Res*. 2014 Dec;4(1):63.
 190. Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, Kulkarni HR, Lassmann M, Klette I, Eiber M, Schwaiger M, Wester HJ. ^{68}Ga - and ^{177}Lu -Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. *J Nucl Med*. 2015 Aug;56(8):1169-76.
 189. Poty S, Désogère P, Šimeček J, Bernhard C, Goncalves V, Goze C, Boschetti F, Notni J, Wester HJ, Denat F. MA-NOTMP: A Triazacyclononane Trimethylphosphinate Based Bifunctional Chelator for Gallium Radiolabelling of Biomolecules. *ChemMedChem*. 2015 Sep;10(9):1475-9.
 188. Mendler CT, Gehring T, Wester HJ, Schwaiger M, Skerra A. ^{89}Zr -Labeled Versus ^{124}I -Labeled αHER2 Fab with Optimized Plasma Half-Life for High-Contrast Tumor Imaging In Vivo. *J Nucl Med*. 2015 Jul;56(7):1112-8.
 187. Baranyai Z, Reich D, Vágner A, Weineisen M, Tóth I, Wester HJ, Notni J. A shortcut to high-affinity Ga-68 and Cu-64 radiopharmaceuticals: one-pot click chemistry trimerisation on the TRAP platform. *Dalton Trans*. 2015 Jun 28;44(24):11137-46.
 186. Maurer T, Weirich G, Schottelius M, Weineisen M, Frisch B, Okur A, Kübler H, Thalgott M, Navab N, Schwaiger M, Wester HJ, Gschwend JE, Eiber M. Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. *Eur Urol*. 2015 Sep;68(3):530-4.
 185. Yousefi BH, von Reutern B, Scherübl D, Manook A, Schwaiger M, Grimmer T, Henriksen G, Förster S, Drzezga A, Wester HJ. FIBT versus florbetaben and PIB: a preclinical comparison study with amyloid-PET in transgenic mice. *EJNMMI Res*. 2015 Mar 28;5:20.
 184. Schottelius M, Šimeček J, Hoffmann F, Willibald M, Schwaiger M, Wester HJ. Twins in spirit - episode I: comparative preclinical evaluation of [(68)Ga]DOTATATE and [(68)Ga]HA-DOTATATE. *EJNMMI Res*. 2015 Apr 10;5:22.
 183. Herrmann K, Bluemel C, Weineisen M, Schottelius M, Wester HJ, Czernin J, Eberlein U, Beykan S, Lapa C, Riedmiller H, Krebs M, Kropf S, Schirbel A, Buck AK, Lassmann M. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. *J Nucl Med*. 2015 Jun;56(6):855-61.
 182. Wester HJ, Keller U, Schottelius M, Beer A, Philipp-Abbrederis K, Hoffmann F, Šimeček J, Gerngross C, Lassmann M, Herrmann K, Pellegata N, Rudelius M, Kessler H, Schwaiger M. Disclosing the CXCR4

- expression in lymphoproliferative diseases by targeted molecular imaging. *Theranostics*. 2015 Mar 1;5(6):618-30.
181. Higuchi T, Yousefi BH, Reder S, Beschoner M, Laitinen I, Yu M, Robinson S, Wester HJ, Schwaiger M, Nekolla SG. Myocardial Kinetics of a Novel [(18)F]-Labeled Sympathetic Nerve PET Tracer LMI1195 in the Isolated Perfused Rabbit Heart. *JACC Cardiovasc Imaging*. 2015 Oct;8(10):1229-31.
180. Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, Graner FP, Kübler H, Haberhorn U, Eisenhut M, Wester HJ, Gschwend JE, Schwaiger M. Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. *J Nucl Med*. 2015 May;56(5):668-74.
179. Gempt J, Bette S, Ryang YM, Buchmann N, Peschke P, Pyka T, Wester HJ, Förster S, Meyer B, Ringel F. ¹⁸F-fluoro-ethyl-tyrosine positron emission tomography for grading and estimation of prognosis in patients with intracranial gliomas. *Eur J Radiol*. 2015 May;84(5):955-62.
178. Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, Lücknerath K, Pietschmann E, Habringer S, Gerngroß C, Franke K, Rudelius M, Schirbel A, Lapa C, Schwamborn K, Steidle S, Hartmann E, Rosenwald A, Kropf S, Beer AJ, Peschel C, Einsele H, Buck AK, Schwaiger M, Götze K, Wester HJ, Keller U. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. *EMBO Mol Med*. 2015 Mar 3;7(4):477-87.
177. Herrmann K, Lapa C, Wester HJ, Schottelius M, Schiepers C, Eberlein U, Bluemel C, Keller U, Knop S, Kropf S, Schirbel A, Buck AK, Lassmann M. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe ⁶⁸Ga-pentixafor. *J Nucl Med*. 2015 Mar;56(3):410-6.
176. Mendler CT, Friedrich L, Laitinen I, Schlapschy M, Schwaiger M, Wester HJ, Skerra A. High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation. *MAbs*. 2015;7(1):96-109.
175. Yousefi BH, Manook A, Grimmer T, Arzberger T, von Reutern B, Henriksen G, Drzezga A, Förster S, Schwaiger M, Wester HJ. Characterization and first human investigation of FIBT, a novel fluorinated Aβ plaque neuroimaging PET radioligand. *ACS Chem Neurosci*. 2015 Mar 18;6(3):428-37.
174. Eiber M, Nekolla SG, Maurer T, Weirich G, Wester HJ, Schwaiger M. (68)Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer. *Abdom Imaging*. 2015 Aug;40(6):1769-71.
173. Schwarzenböck SM, Gertz J, Souvatzoglou M, Kurth J, Sachs D, Nawroth R, Treiber U, Schuster T, Senekowitsch-Schmidtke R, Schwaiger M, Ziegler SI, Henriksen G, Wester HJ, Krause BJ. Comparison of [¹¹C]choline ([¹¹C]CHO) and S(+)-β-methyl-[¹¹C]choline ([¹¹C]SMC) as imaging probes for prostate cancer in a PC-3 prostate cancer xenograft model. *Mol Imaging Biol*. 2015 Apr;17(2):248-56.
172. Hartmann H, Freudenberg R, Oehme L, Zöphel K, Schottelius M, Wester HJ, Wunderlich G, Kotzerke J, Brogssitter C. Dosimetric measurements of (68)Ga-high affinity DOTATATE: twins in spirit - part III. *Nuklearmedizin*. 2014;53(5):211-6.
171. Maurer T, Beer AJ, Wester HJ, Kübler H, Schwaiger M, Eiber M. Positron emission tomography/magnetic resonance imaging with ⁶⁸Gallium-labeled ligand of prostate-specific membrane antigen: promising novel option in prostate cancer imaging? *Int J Urol*. 2014 Dec;21(12):1286-8.
170. Herrmann K, Buck AK, Schuster T, Abbrederis K, Blümel C, Santi I, Rudelius M, Wester HJ, Peschel C, Schwaiger M, Dechow T, Keller U. Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL. *Oncotarget*. 2014 Jun 30;5(12):4050-9.
169. Pyka T, Gempt J, Ringel F, Hüttinger S, van Marwick S, Nekolla S, Wester HJ, Schwaiger M, Förster S. Prediction of glioma recurrence using dynamic ¹⁸F-fluoroethyltyrosine PET. *AJNR Am J Neuroradiol*. 2014 Oct;35(10):1924-9.
168. Notni J, Simecek J, Wester HJ. Phosphinic Acid Functionalized Polyazacycloalkane Chelators for Radiodiagnostics and Radiotherapeutics: Unique Characteristics and Applications. *ChemMedChem*. 2014 Apr 3.[Epub ahead of print]
167. Simecek J, Notni J, Kapp TG, Kessler H, Wester HJ. Benefits of NOPO As Chelator in Gallium-68 Peptides, Exemplified by Preclinical Characterization of (68)Ga-NOPO-c(RGDfK). *Mol Pharm*. 2014 May 5;11(5):1687-95.
166. Trajkovic-Arsic M, Mohajerani P, Sarantopoulos A, Kalideris E, Steiger K, Esposito I, Ma X, Themelis G, Burton N, Michalski CW, Kleeff J, Stangl S, Beer AJ, Pohle K, Wester HJ, Schmid RM, Braren R, Ntziachristos V, Siveke JT. Multimodal molecular imaging of integrin avb3 for in vivo detection of pancreatic cancer. *J Nucl Med*. 2014 Mar;55(3):446-51.
165. Brogssitter C, Zöphel K, Hartmann H, Schottelius M, Wester HJ, Kotzerke J. Twins in spirit part II: DOTATATE and high-affinity DOTATATE-the clinical experience. *Eur J Nucl Med Mol Imaging*. 2014 Jun;41(6):1158-65.
164. Beer AJ, Pelisek J, Heider P, Saraste A, Reeps C, Metz S, Seidl S, Kessler H, Wester HJ, Eckstein HH, Schwaiger M. PET/CT Imaging of Integrin αvβ3 Expression in Human Carotid Atherosclerosis. *JACC Cardiovasc Imaging*. 2014 Feb;7(2):178-87.
163. Simecek J, Zemek O, Hermann P, Notni J, Wester HJ. Tailored Gallium(III)Chelator NOPO: Synthesis, Characterization, Bioconjugation, and Application in Preclinical Ga-68-PET Imaging. *Mol Pharm*. 2013 Dec 18.
162. Martin R, Jüttler S, Müller M, Wester HJ. Cationic eluate pretreatment for automated synthesis of [(68)Ga]CPCr4.2. *Nucl Med Biol*. 2014 Jan;41(1):84-9
161. Neubauer S, Rechenmacher F, Beer AJ, Curnis F, Pohle K, D'Alessandria C, Wester HJ, Reuning U, Corti A, Schwaiger M, Kessler H. Selective Imaging of the Angiogenic Relevant Integrins α5β1 and αvβ3. *Angew Chem Int Ed Engl*. 2013 Oct 25;52(44):11656-9.
160. Beyer T, Hacker M, Schubiger A, Virgolini I, Wester HJ. Nuclear medicine 2013: from status quo to status go. *Eur J Nucl Med Mol Imaging*. 2013 Dec;40(12):1794-6.

159. Brogsitter C, Schottelius M, Zöphel K, Kotzerke J, Wester HJ. Erratum to: Twins in spirit: DOTATATE and high-affinity DOTATATE. *Eur J Nucl Med Mol Imaging*. 2014 Feb;41(2):402.
158. Brogsitter C, Schottelius M, Zöphel K, Kotzerke J, Wester HJ. Twins in spirit: DOTATATE and high-affinity DOTATATE. *Eur J Nucl Med Mol Imaging*. 2013 Oct;40(11):1789.
157. Notni J, Hermann P, Dregely I, Wester HJ. Convenient synthesis of (68)Ga-labeled gadolinium(III) complexes: towards bimodal responsive probes for functional imaging with PET/MRI. *Chemistry*. 2013 Sep 16;19(38):12602-6.
158. Smolarz K, Krause BJ, Graner FP, Wagner FM, Wester HJ, Sell T, Bacher-Stier C, Fels L, Dinkelborg L, Schwaiger M. Biodistribution and radiation dosimetry in healthy volunteers of a novel tumour-specific probe for PET/CT imaging: BAY 85-8050. *Eur J Nucl Med Mol Imaging*. 2013 Dec;40(12):1861-8.
158. Brogsitter C, Schottelius M, Zöphel K, Kotzerke J, Wester HJ. Twins in spirit: DOTATATE and high-affinity DOTATATE. *Eur J Nucl Med Mol Imaging*. 2013 Oct;40(11):1789
157. Wagner JY, Schwarz K, Schreiber S, Schmidt B, Wester HJ, Schwaiger M, Peschel C, von Schilling C, Scheidhauer K, Keller U. Myeloablative Anti-CD20 Radioimmunotherapy +/- High-Dose Chemotherapy Followed by Autologous Stem Cell Support for Relapsed/Refractory B-Cell Lymphoma Results in Excellent Long-Term Survival. *Oncotarget*. 2013 Jun;4(6):899-910
156. Laitinen I, Notni J, Pohle K, Rudelius M, Farrell E, Nekolla SG, Henriksen G, Neubauer S, Kessler H, Wester HJ, Schwaiger M. Comparison of cyclic RGD peptides for $\alpha\beta_3$ integrin detection in a rat model of myocardial infarction. *EJNMMI Res*. 2013 May 11;3(1):38.
155. Simecek J, Hermann P, Havlíčková J, Herdtweck E, Kapp TG, Engelbogen N, Kessler H, Wester HJ, Notni J. A Cyclen-Based Tetraphosphinate Chelator for the Preparation of Radiolabeled Tetrameric Bioconjugates. *Chemistry*. 2013 Jun 10;19(24):7748-57
154. Schwarzenböck S, Sachs D, Souvatzoglou M, Schuster T, Nawroth R, Weirich G, Treiber U, Wester HJ, Ziegler S, Schwaiger M, Senekowitsch-Schmidtke R, Krause BJ. [¹¹C]choline as a pharmacodynamic marker for docetaxel therapy. *Nuklearmedizin*. 2013;52(4):141-7..
153. Shen Y, Schottelius M, Zelenka K, De Simone M, Pohle K, Kessler H, Wester HJ, Schmutz P, Alberto R. Orthogonally protected artificial amino acid as tripod ligand for automated peptide synthesis and labeling with [(99m)Tc(OH(2))(3)(CO)(3)](+). *Bioconjug Chem*. 2013 Jan 16;24(1):26-35. doi:
152. Simecek J, Hermann P, Wester HJ, Notni J. How is (68)Ga labeling of macrocyclic chelators influenced by metal ion contaminants in (68)Ge/(68)Ga generator eluates? *ChemMedChem*. 2013 Jan;8(1):95-103.
151. Graf N, Herrmann K, Nummerger B, Zwisler D, Aichler M, Feuchtinger A, Schuster T, Wester HJ, Senekowitsch-Schmidtke R, Peschel C, Schwaiger M, Keller U, Dechow T, Buck AK. [¹⁸F]FLT is superior to [¹⁸F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner. *Eur J Nucl Med Mol Imaging*. 2013 Jan;40(1):34-43.
150. Förster S, Yousefi BH, Wester HJ, Klupp E, Rominger A, Förstl H, Kurz A, Grimmer T, Drzezga A. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease. *Eur J Nucl Med Mol Imaging*. 2012 Dec;39(12):1927-36.
149. Notni J, Pohle K, Wester HJ. Be spoiled for choice with radiolabelled RGD peptides: preclinical evaluation of ⁶⁸Ga-TRAP(RGD)₃. *Nucl Med Biol*. 2013 Jan;40(1):33-41
148. Simecek J, Wester HJ, Notni J. Copper-64 labelling of triazacyclononane-triphosphinate chelators. *Dalton Trans*. 2012 Dec 7;41(45):13803-6.
147. Demmer O, Frank AO, Hagn F, Schottelius M, Marinelli L, Cosconati S, Brack-Werner R, Kremb S, Wester HJ, Kessler H. A conformationally frozen peptoid boosts CXCR4 affinity and anti-HIV activity. *Angew Chem Int Ed Engl*. 2012 Aug 6;51(32):8110-3.
146. Buck D, Förschler A, Lapa C, Schuster T, Vollmar P, Korn T, Nessler S, Stadelmann C, Drzezga A, Buck AK, Wester HJ, Zimmer C, Krause BJ, Hemmer B. 18F-FDG PET detects inflammatory infiltrates in spinal cord experimental autoimmune encephalomyelitis lesions. *J Nucl Med*. 2012 Aug;53(8):1269-76. doi:
145. Simecek J, Zemek O, Hermann P, Wester HJ, Notni J. A monoreactive bifunctional triazacyclononane phosphinate chelator with high selectivity for gallium-68. *ChemMedChem*. 2012 Aug;7(8):1375-8.
144. Notni J, Pohle K, Wester HJ. Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET. *EJNMMI Res*. 2012 Jun 9;2(1):28.
143. Heine M, Freund B, Nielsen P, Jung C, Reimer R, Hohenberg H, Zangemeister-Wittke U, Wester HJ, Lüers GH, Schumacher U. High interstitial fluid pressure is associated with low tumour penetration of diagnostic monoclonal antibodies applied for molecular imaging purposes. *PLoS One*. 2012;7(5):e36258.
142. Saraste A, Laitinen I, Weidl E, Wildgruber M, Weber AW, Nekolla SG, Hölzlwimmer G, Esposito I, Walch A, Leppänen P, Lisinen I, Luppä PB, Ylä-Herttuala S, Wester HJ, Knuuti J, Schwaiger M. Diet intervention reduces uptake of $\alpha\beta_3$ integrin-targeted PET tracer 18F-galacto-RGD in mouse atherosclerotic plaques. *J Nucl Cardiol*. 2012 Aug;19(4):775-84.
141. Notni J, Plutnar J, Wester HJ. Bone-seeking TRAP conjugates: surprising observations and their implications on the development of gallium-68-labeled bisphosphonates. *EJNMMI Res*. 2012 Mar 30;2(1):13. doi: 10.1186/2191-219X-2-13.
140. Wester HJ. [GMP production.Shaping the future]. *Nuklearmedizin*. 2012;51(1):N1-4. German.
139. Manook A, Yousefi BH, Willuweit A, Platzer S, Reder S, Voss A, Huisman M, Settles M, Neff F, Velden J, Schoor M, von der Kammer H, Wester HJ, Schwaiger M, Henriksen G, Drzezga A. Small-animal PET imaging of amyloid-beta plaques with [¹¹C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease. *PLoS One*. 2012;7(3):e31310.

138. Gaertner FC, Kessler H, Wester HJ, Schwaiger M, Beer AJ. Radiolabelled RGD peptides for imaging and therapy. *Eur J Nucl Med Mol Imaging*. 2012 Feb;39 Suppl 1:S126-38
137. Sherif HM, Saraste A, Nekolla SG, Weidl E, Reder S, Tapfer A, Rudelius M, Higuchi T, Botnar RM, Wester HJ, Schwaiger M. Molecular Imaging of Early $\alpha v \beta 3$ Integrin Expression Predicts Long-Term Left-Ventricle Remodeling After Myocardial Infarction in Rats. *J Nucl Med*. 2012 Feb;53(2):318-23.
136. Herrmann K, Erkan M, Dobritz M, Schuster T, Siveke JT, Beer AJ, Wester HJ, Schmid RM, Friess H, Schwaiger M, Kleeff J, Buck AK. Comparison of 3'-deoxy-3'-[18-F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours. *Eur J Nucl Med Mol Imaging*. 2012 May;39(5):846-51
135. Schwaiger M, Wester HJ. How many PET tracers do we need? *J Nucl Med*. 2011 Dec; 52 Suppl 2:36S-41S.
134. Kostikov AP, Chin J, Orchowski K, Niedermoser S, Kovacevic MM, Aliaga A, Jurkschat K, Wängler B, Wängler C, Wester HJ, Schirmacher R. Oxalic acid supported Si-18F-radiofluorination: one-step radiosynthesis of N-succinimidyl 3-(di-tert-butyl[18F]fluorosilyl)benzoate ([18F]SiFB) for protein labeling. *Bioconjug Chem*. 2012 Jan 18; 23(1):106-14.
133. Notni J, Šimeček J, Hermann P, Wester HJ. TRAP, a powerful and versatile framework for gallium-68 radiopharmaceuticals. *Chemistry*. 2011 Dec 23;17(52):14718-22.
132. Herrmann K, Buck AK, Schuster T, Rudelius M, Wester HJ, Graf N, Scheuerer C, Peschel C, Schwaiger M, Dechow T, Keller U. A pilot study to evaluate 3'-deoxy-3'-18F-fluorothymidine pet for initial and early response imaging in mantle cell lymphoma. *J Nucl Med*. 2011 Dec;52(12):1898-902.
131. Gourni E, Demmer O, Schottelius M, D'Alessandria C, Schulz S, Dijkgraaf I, Schumacher U, Schwaiger M, Kessler H, Wester HJ. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent. *J Nucl Med*. 2011 Nov;52(11):1803-10.
130. Wessmann SH, Henriksen G, Wester HJ. Cryptate mediated nucleophilic 18F-fluorination without azeotropic drying. *Nuklearmedizin*. 2012 Feb 16;50(1):1-8.
129. Demmer O, Dijkgraaf I, Schumacher U, Marinelli L, Cosconati S, Gourni E, Wester HJ, Kessler H. Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4. *J Med Chem*. 2011 Nov 10;54(21):7648-62.
128. Al-Ibraheem A, Bundschuh RA, Notni J, Buck A, Winter A, Wester HJ, Schwaiger M, Scheidhauer K. Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours? *Eur J Nucl Med Mol Imaging*. 2011 Nov; 38(11): 2005-13.
127. Demmer O, Gourni E, Schumacher U, Kessler H, Wester HJ. PET imaging of CXCR4 receptors in cancer by a new optimized ligand. *ChemMedChem*. 2011 Oct 4;6(10):1789-91.
126. Miederer M, Molatore S, Marinoni I, Perren A, Spitzweg C, Reder S, Wester HJ, Buck AK, Schwaiger M, Pellegata NS. Functional Imaging of Pheochromocytoma with Ga-DOTATOC and C-HED in a Genetically Defined Rat Model of Multiple Endocrine Neoplasia. *Int J Mol Imaging*. 2011;2011:175352.
125. Förster S, Grimm T, Miederer I, Henriksen G, Yousefi BH, Graner P, Wester HJ, Förstl H, Kurz A, Dickerson BC, Bartenstein P, Drzezga A. Regional Expansion of Hypometabolism in Alzheimer's Disease Follows Amyloid Deposition with Temporal Delay. *Biol Psychiatry*. 2012 May 1;71(9):792-7.
124. Grosu AL, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F, Schwaiger M, Molls M, Wester HJ, Weber WA. An Interindividual Comparison of O-(2-[(18F)Fluoroethyl]-L-Tyrosine (FET)- and L-[Methyl-(11C)]Methionine (MET)-PET in Patients With Brain Gliomas and Metastases. *Int J Radiat Oncol Biol Phys*. 2011 May 11.
123. Beer AJ, Kessler H, Wester HJ, Schwaiger M. PET Imaging of Integrin $\alpha v \beta 3$ Expression. *Theranostics*. 2011; 1: 48-57.
122. Ott K, Herrmann K, Schuster T, Langer R, Becker K, Wieder HA, Wester HJ, Siewert JR, Büschenfelde CM, Buck AK, Wilhelm D, Ebert MP, Peschel C, Schwaiger M, Lordick F, Krause BJ. Molecular Imaging of Proliferation and Glucose Utilization: Utility for Monitoring Response and Prognosis after Neoadjuvant Therapy in Locally Advanced Gastric Cancer. *Ann Surg Oncol*. 2011 Nov;18(12):3316-23.
121. Herrmann K, Buck AK, Schuster T, Junger A, Wieder H, Graf N, Ringshausen I, Rudelius M, Wester HJ, Schwaiger M, Keller U, Dechow T. Predictive Value of Initial 18F-FLT Uptake in Patients with Aggressive Non-Hodgkin Lymphoma Receiving R-CHOP Treatment. *J Nucl Med*. 2011 May;52(5):690-6.
120. Yousefi BH, Manook A, Drzezga A, von Reutern B, Schwaiger M, Wester HJ, Henriksen G. Synthesis and evaluation of 11C-labeled imidazo[2,1-b]benzothiazoles (IBTs) as PET tracers for imaging β -amyloid plaques in Alzheimer's disease. *J Med Chem*. 2011 Feb 24;54(4):949-56.
119. Waengler C, Waser B, Alke A, Iovkova L, Buchholz HG, Niedermoser S, Jurkschat K, Fottner C, Bartenstein P, Schirmacher R, Reubi JC, Wester HJ, Wängler B. One-Step (18F)-Labeling of Carbohydrate-Conjugated Octeotate-Derivatives Containing a Silicon-Fluoride-Acceptor (SiFA): In Vitro and In Vivo Evaluation as Tumor Imaging Agents for Positron Emission Tomography (PET). *Bioconjug Chem*. 2010 Dec 15;21(12):2289-96
118. Höfling SB, Maschauer S, Hübner H, Gmeiner P, Wester HJ, Prante O, Heinrich MR. Synthesis, biological evaluation and radiolabelling by 18F-fluoroarylation of a dopamine D3-selective ligand as prospective imaging probe for PET. *Bioorg Med Chem Lett*. 2010 Dec 1;20(23):6933-7.
117. Metz S, Ganter C, Lorenzen S, van Marwick S, Herrmann K, Lordick F, Nekolla SG, Rummeny EJ, Wester HJ, Brix G, Schwaiger M, Beer AJ. Phenotyping of tumor biology in patients by multimodality multiparametric imaging: relationship of microcirculation, $\alpha v \beta 3$ expression, and glucose metabolism. *J Nucl Med*. 2010 Nov;51(11):1691-8.
116. Krause BJ, Souvatzoglou M, Herrmann K, Weber AW, Schuster T, Buck AK, Nawroth R, Weirich G, Treiber U, Wester HJ, Ziegler SI, Senekowitsch-Schmidtke R, Schwaiger M. [11C]Choline as pharmacodynamic marker

- for therapy response assessment in a prostate cancer xenograft model. *Eur J Nucl Med Mol Imaging*. 2010 Oct;37(10):1861-8.
115. Beer AJ, Eiber M, Souvatzoglou M, Holzapfel K, Ganter C, Weirich G, Maurer T, Kübler H, Wester HJ, Gaa J, Krause BJ. Restricted Water Diffusibility as Measured by Diffusion-weighted MR Imaging and Choline Uptake in [¹¹C]Choline PET/CT are Correlated in Pelvic Lymph Nodes in Patients with Prostate Cancer. *Mol Imaging Biol*. 2011 Apr;13(2):352-61
 114. Liu S, Liu Z, Chen K, Yan Y, Watzlowik P, Wester HJ, Chin FT, Chen X. 18F-labeled galacto and PEGylated RGD dimers for PET imaging of $\alpha v \beta 3$ integrin expression. *Mol Imaging Biol*. 2010 Oct;12(5):530-8.
 113. Laitinen I, Saraste A, Weidl E, Poethko T, Weber AW, Nekolla SG, Leppänen P, Ylä-Herttua S, Hölzlwimmer G, Walch A, Esposito I, Wester HJ, Knuuti J, Schwaiger M. Evaluation of alphavbeta3 integrin-targeted positron emission tomography tracer 18F-galacto-RGD for imaging of vascular inflammation in atherosclerotic mice. *Circ Cardiovasc Imaging*. 2009 Jul;2(4):331-8.
 112. Sherif HM, Saraste A, Weidl E, Weber AW, Higuchi T, Reder S, Poethko T, Henriksen G, Casebier D, Robinson S, Wester HJ, Nekolla SG, Schwaiger M. Evaluation of a novel (18)F-labeled positron-emission tomography perfusion tracer for the assessment of myocardial infarct size in rats. *Circ Cardiovasc Imaging*. 2009 Mar;2(2):77-84.
 111. Marton J, Schoultz BW, Hjørnevik T, Drzezga A, Yousefi BH, Wester HJ, Willoch F, Henriksen G. Synthesis and Evaluation of a Full-Agonist Orvinol for PET-Imaging of Opioid Receptors: [(11)C]PEO. *J Med Chem*. 2009 Aug 20.
 110. Eckel F, Herrmann K, Schmidt S, Hillerer C, Wieder HA, Krause BJ, Schuster T, Langer R, Wester HJ, Schmid RM, Schwaiger M, Buck AK. Imaging of Proliferation in Hepatocellular Carcinoma with the In Vivo Marker 18F-Fluorothymidine. *J Nucl Med*. 2009 Sep;50(9):1441-7.
 109. Schottelius M, Laufer B, Kessler H, Wester HJ. Ligands for mapping alphavbeta3-integrin expression in vivo. *Acc Chem Res*. 2009 Jul 21;42(7):969-80.
 108. Schnell O, Krebs B, Carlsen J, Miederer I, Goetz C, Goldbrunner RH, Wester HJ, Haubner R, Pöpperl G, Holtmannspötter M, Kretschmar HA, Kessler H, Tonn JC, Schwaiger M, Beer AJ. Imaging of integrin $\{\alpha\}v\{\beta\}3$ expression in patients with malignant glioma by [18F]galacto-RGD positron emission tomography. *Neuro Oncol*. 2009 Dec;11(6):861-70..
 107. Nekolla SG, Reder S, Saraste A, Higuchi T, Dzewas G, Preissel A, Huisman M, Poethko T, Schuster T, Yu M, Robinson S, Casebier D, Henke J, Wester HJ, Schwaiger M. Evaluation of the novel myocardial perfusion positron-emission tomography tracer 18F-BMS-747158-02: comparison to 13N-ammonia and validation with microspheres in a pig model. *Circulation*. 2009 May 5;119(17):2333-42.
 106. Hultsch C, Schottelius M, Auernheimer J, Alke A, Wester HJ. (18)F-Fluoroglucosylation of peptides, exemplified on cyclo(RGDfK). *Eur J Nucl Med Mol Imaging*. 2009 Sep;36(9):1469-74.
 105. Drzezga A, Grimmer T, Henriksen G, Mühlau M, Perneczky R, Miederer I, Praus C, Sorg C, Wohlschläger A, Riemenschneider M, Wester HJ, Foerstl H, Schwaiger M, Kurz A. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. *Neurology*. 2009 Apr 28;72(17):1487-94
 104. Schottelius M, Wester HJ. Molecular imaging targeting peptide receptors. *Methods*. 2009 Jun;48(2):161-77.
 103. Buck AK, Herrmann K, Shen C, Dechow T, Schwaiger M, Wester HJ. Molecular imaging of proliferation in vivo: positron emission tomography with [18F]fluorothymidine. *Methods*. 2009 Jun;48(2):205-15.
 102. Grimmer T, Riemenschneider M, Förstl H, Henriksen G, Klunk WE, Mathis CA, Shiga T, Wester HJ, Kurz A, Drzezga A. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. *Biol Psychiatry*. 2009 Jun 1;65(11):927-34.
 101. Langer R, Ott K, Specht K, Becker K, Lordick F, Burian M, Herrmann K, Schratzenholz A, Cahill MA, Schwaiger M, Hofler H, Wester HJ. Protein expression profiling in esophageal adenocarcinoma patients indicates association of heat-shock protein 27 expression and chemotherapy response. *Clin Cancer Res*. 2008 Dec 15;14(24):8279-87.
 100. Wester HJ, Schoultz BW, Hultsch C, Henriksen G. Fast and repetitive in-capillary production of [18F]FDG. *Eur J Nucl Med Mol Imaging*. 2009 Apr;36(4):653-8
 99. Miederer M, Seidl S, Buck A, Scheidhauer K, Wester HJ, Schwaiger M, Perren A. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. *Eur J Nucl Med Mol Imaging*. 2009 Jan;36(1):48-52.
 98. Higuchi T, Nekolla SG, Huisman MM, Reder S, Poethko T, Yu M, Wester HJ, Casebier DS, Robinson SP, Botnar RM, Schwaiger M. A new 18F-labeled myocardial PET tracer: myocardial uptake after permanent and transient coronary occlusion in rats. *J Nucl Med*. 2008 Oct;49(10):1715-22.
 97. Dijkgraaf I, Beer AJ, Wester HJ. Application of RGD-containing peptides as imaging probes for alphavbeta3 expression. *Front Biosci*. 2009;14:887-899
 96. Hultsch C, Blank O, Wester HJ, Heinrich MR. Radical fluoroarylation in radiochemical synthesis. *Tetrahedron Lett* 2008;49:881-3
 95. Berndt U, Stanetty C, Wanek T, Kuntner C, Stanek J, Berger M, Bauer M, Henriksen G, Wester HJ, Kvaternik H, Angelberger P, Noe C. Synthesis of a [F-18]fluorobenzothiazole as potential amyloid imaging agent. *J Label Compds Radiopharm*. (2008);51(3-4):37-145
 94. Höfling SB, Hultsch C, Wester HJ, Heinrich MR. Radiochemical F-18-fluoroarylation of unsaturated alpha-, beta- and gamma-amino acids, application to a radiolabelled analogue of baclofen. *Tetrahedron* (2008); 64(52): 11846- 11851

93. Graf N, Herrmann K, den Hollander J, Fend F, Schuster T, Wester HJ, Senekowitsch-Schmidtke R, zum Büschenfelde CM, Peschel C, Schwaiger M, Dechow T, Buck AK. Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment. *Mol Imaging Biol.* 2008 Nov-Dec;10(6):349-55.
92. Herrmann K, Eckel F, Schmidt S, Scheidhauer K, Krause BJ, Kleeff J, Schuster T, Wester HJ, Friess H, Schmid RM, Schwaiger M, Buck AK.. In vivo characterization of proliferation for discriminating cancer from pancreatic pseudotumors. *J Nucl Med.* 2008 Sep;49(9):1437-44.
91. Tuncel M, Souvatzoglou M, Herrmann K, Stollfuss J, Schuster T, Weirich G, Wester HJ, Schwaiger M, Krause BJ. [11C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. *Nucl Med Biol.* 2008 Aug;35(6):689-95.
90. Buck AK, Nekolla S, Ziegler S, Beer A, Krause BJ, Herrmann K, Scheidhauer K, Wester HJ, Rummeny EJ, Schwaiger M, Drzezga A. SPECT/CT. *J Nucl Med.* 2008 Aug;49(8):1305-19.
89. Dijkraaf I, Wester HJ. Peptides, multimers and polymers. *Handb Exp Pharmacol.* 2008;(185 Pt 2):61-92. Review.
88. Schottelius M, Berger S, Poethko T, Schwaiger M, Wester HJ. Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency. *Bioconjug Chem.* 2008 Jun;19(6):1256-68.
87. Buck AK, Herrmann K, Büschenfelde CM, Juweid ME, Bischoff M, Glattig G, Weirich G, Möller P, Wester HJ, Scheidhauer K, Dechow T, Peschel C, Schwaiger M, Reske SN. Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine. *Clin Cancer Res.* 2008 May 15;14(10):2970-7.
86. Demmer O, Dijkgraaf I, Schottelius M, Wester HJ, Kessler H. Introduction of functional groups into peptides via N-alkylation. *Org Lett.* 2008 May 15;10(10):2015-8.
85. Decristoforo C, Hernandez Gonzalez I, Carlsen J, Rupprich M, Huisman M, Virgolini I, Wester HJ, Haubner R. 68Ga- and 111In-labelled DOTA-RGD peptides for imaging of $\alpha v \beta 3$ integrin expression. *Eur J Nucl Med Mol Imaging.* 2008 Aug;35(8):1507-15.
84. Grimmer T, Henriksen G, Wester HJ, Förstl H, Klunk WE, Mathis CA, Kurz A, Drzezga A.. Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. *Neurobiol Aging.* 2009 Dec;30(12):1902-9
83. Picchio M, Beck R, Haubner R, Seidl S, Machulla HJ, Johnson TD, Wester HJ, Reischl G, Schwaiger M, Piert M. Intratumoral spatial distribution of hypoxia and angiogenesis assessed by 18F-FAZA and 125I-Gluco-RGD autoradiography. *J Nucl Med.* 2008 Apr;49(4):597-605.
82. Huisman MC, Higuchi T, Reder S, Nekolla SG, Poethko T, Wester HJ, Ziegler SI, Casebier DS, Robinson SP, Schwaiger M. Initial characterization of an 18F-labeled myocardial perfusion tracer. *J Nucl Med.* 2008 Apr;49(4):630-6.
81. Langer R, Feith M, Siewert JR, Wester HJ, Hoefler H. Expression and clinical significance of glucose regulated proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus. *BMC Cancer.* 2008 Mar 10;8:70.
80. Higuchi T, Bengel FM, Seidl S, Watzlowik P, Kessler H, Hegenloh R, Reder S, Nekolla SG, Wester HJ, Schwaiger M. Assessment of $\alpha v \beta 3$ integrin expression after myocardial infarction by positron emission tomography. *Cardiovasc Res.* 2008 May 1;78(2):395-403.
79. Henriksen G, Yousefi BH, Drzezga A, Wester HJ. Development and evaluation of compounds for imaging of beta-amyloid plaque by means of positron emission tomography. *Eur J Nucl Med Mol Imaging.* 2008 Mar;35 Suppl 1:S75-81. Review.
78. Beer AJ, Niemeyer M, Carlsen J, Sarbia M, Nährig J, Watzlowik P, Wester HJ, Harbeck N, Schwaiger M. Patterns of $\alpha v \beta 3$ expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. *J Nucl Med.* 2008 Feb;49(2):255-9.
77. Beer AJ, Lorenzen S, Metz S, Herrmann K, Watzlowik P, Wester HJ, Peschel C, Lordick F, Schwaiger M. Comparison of integrin $\alpha v \beta 3$ expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. *J Nucl Med.* 2008 Jan;49(1):22-9.
76. Beer AJ, Grosu AL, Carlsen J, Kolk A, Sarbia M, Stangier I, Watzlowik P, Wester HJ, Haubner R, Schwaiger M. [18F]galacto-RGD positron emission tomography for imaging of $\alpha v \beta 3$ expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. *Clin Cancer Res.* 2007 Nov 15;13:6610-6.
75. Herrmann K, Ott K, Buck AK, Lordick F, Wilhelm D, Souvatzoglou M, Becker K, Schuster T, Wester HJ, Siewert JR, Schwaiger M, Krause BJ. Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis. *J Nucl Med.* 2007 Dec;48(12):1945-50.
74. Drzezga A, Grimmer T, Henriksen G, Stangier I, Pernecky R, Diehl-Schmid J, Mathis CA, Klunk WE, Price J, DeKosky S, Wester HJ, Schwaiger M, Kurz A.. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. *Neuroimage.* 2008 Jan 15;39(2):619-33.
73. Wieder H, Beer AJ, Poethko T, Meisetschlaeger G, Wester HJ, Rummeny E, Schwaiger M, Stahl AR. PET/CT with Gluc-Lys-([18F]FP)-TOCA: correlation between uptake, size and arterial perfusion in somatostatin receptor positive lesions. *Eur J Nucl Med Mol Imaging.* 2008 Feb;35(2):264-71.
72. Grosu AL, Souvatzoglou M, Röper B, Dobritz M, Wiedenmann N, Jacob V, Wester HJ, Reischl G, Machulla HJ, Schwaiger M, Molls M, Piert M. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. *Int J Radiat Oncol Biol Phys.* 2007 Oct 1;69(2):541-51.
71. Stahl AR, Wagner B, Poethko T, Perutka M, Wester HJ, Essler M, Heemann U, Schwaiger M, Lutz J. Renal accumulation of [111In]DOTATOC in rats: influence of inhibitors of the organic ion transport and diuretics. *Eur J Nucl Med Mol Imaging.* 2007 Dec;34(12):2129-34.

70. Schlapschy M, Theobald I, Mack H, Schottelius M, Wester HJ, Skerra A. Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life. *Protein Eng Des Sel*. 2007 Jun;20(6):273-84.
69. Herrmann K, Wieder HA, Buck AK, Schöffel M, Krause BJ, Fend F, Schuster T, Meyer zum Büschenfelde C, Wester HJ, Duyster J, Peschel C, Schwaiger M, Dechow T. Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. *Clin Cancer Res*. 2007 Jun 15;13(12):3552-8.
68. Wester HJ. Nuclear imaging probes: from bench to bedside. *Clin Cancer Res*. 2007, 13(12):3470-81. Review.
67. Knör S, Modlinger A, Poethko T, Schottelius M, Wester HJ, Kessler H. Synthesis of novel 1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic acid (DOTA) derivatives for chemoselective attachment to unprotected polyfunctionalized compounds. *Chemistry*. 2007;13(21):6082-90.
66. Higuchi T, Wester HJ, Schwaiger M. Imaging of angiogenesis in cardiology. *Eur J Nucl Med Mol Imaging*. 2007 Jun;34 Suppl 1:S9-19. Review.
65. Souvatzoglou M, Grosu AL, Röper B, Krause BJ, Beck R, Reischl G, Picchio M, Machulla HJ, Wester HJ, Piert M. Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study. *Eur J Nucl Med Mol Imaging*. 2007 Oct;34(10):1566-75.
64. Makrides V, Bauer R, Weber W, Wester HJ, Fischer S, Hinz R, Huggel K, Opfermann T, Herzau M, Ganapathy V, Verrey F, Brust P. Preferred transport of O-(2-[18F]fluoroethyl)-D-tyrosine (D-FET) into the porcine brain. *Brain Res*. 2007 May 25;1147:25-33.
63. Henriksen G, Hauser AI, Westwell AD, Yousefi BH, Schwaiger M, Drzezga A, Wester HJ. Metabolically stabilized benzothiazoles for imaging of amyloid plaques. *J Med Chem*. 2007 Mar 22;50(6):1087-9.
62. Prante O, Einsiedel J, Haubner R, Gmeiner P, Wester HJ, Kuwert T, Maschauer S. 3,4,6-Tri-O-acetyl-2-deoxy-2-[18F]fluoroglucofuranosyl phenylthiosulfonate: a thiol-reactive agent for the hemoselective 18F-glycosylation of peptides. *Bioconj Chem*. 2007 Jan-Feb;18(1):254-62.
61. Wester HJ, Schottelius M. Fluorine-18 labeling of peptides and proteins. *Ernst Schering Res Found Workshop*. 2007;(62):79-111. Review.
60. Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, Schnell O, Niemeyer M, Kessler H, Wester HJ, Weber WA, Schwaiger M. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin $\alpha v \beta 3$ expression in man. *Clin Cancer Res*. 2006;12(13):3942-9.
59. Scheuenpflug M, Günther D, Wester H.J., Lüth T. Laserbearbeitung von glasartigem Kohlenstoff. *wt Werkstatttechnik*, 2006, 11/12.
58. Scher B, Seitz M, Albinger W, Tiling R, Scherr M, Becker HC, Souvatzoglou M, Gildehaus FJ, Wester HJ, Dresel S. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. *Eur J Nucl Med Mol Imaging*. 2007;34(1):45-54
57. Henriksen G, Spilker ME, Sprenger T, Hauser AI, Platzer S, Boecker H, Toelle TR, Schwaiger M, Wester HJ. Gender dependent rate of metabolism of the opioid receptor-PET ligand [18F]fluoroethylidiprenorphine. *Nuklearmedizin*. 2006;45(5):197-200.
56. Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, Schnell O, Niemeyer M, Kessler H, Wester HJ, Weber WA, Schwaiger M. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin $\alpha v \beta 3$ expression in man. *Clin Cancer Res*. 2006;12(13):3942-9.
55. Rstad E, Platzer S, Berthele A, Pilowsky LS, Luthra SK, Wester HJ, Henriksen G. Towards NR2B receptor selective imaging agents for PET-synthesis and evaluation of N-[11C]-(2-methoxy)benzyl (E)-styrene-, 2-naphthyl- and 4-trifluoromethoxyphenylamidide. *Bioorg Med Chem*. 2006;14(18):6307-13.
54. Stahl A, Schachoff S, Beer A, Winter A, Wester HJ, Scheidhauer K, Schwaiger M, Wolf I. [111In]DOTATOC as a dosimetric substitute for kidney dosimetry during [90Y]DOTATOC therapy: results and evaluation of a combined gamma camera/probe approach. *Eur J Nucl Med Mol Imaging*. 2006 Nov;33(11):1328-36.
53. Beer AJ, Haubner R, Wolf I, Goebel M, Luderschmidt S, Niemeyer M, Grosu AL, Martinez MJ, Wester HJ, Weber WA, Schwaiger M. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging $\alpha v \beta 3$ expression. *J Nucl Med*. 2006 May;47(5):763-9.
52. Sprenger T, Willoch F, Miederer M, Schindler F, Valet M, Berthele A, Spilker ME, Forderreuther S, Straube A, Stangier I, Wester HJ, Tolle TR. Opioidergic changes in the pineal gland and hypothalamus in cluster headache: a ligand PET study. *Neurology*. 2006 Apr 11;66(7):1108-10.
51. Meisetschlager G, Poethko T, Stahl A, Wolf I, Scheidhauer K, Schottelius M, Herz M, Wester HJ, Schwaiger M. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. *J Nucl Med*. 2006 Apr;47(4):566-73.
50. Bruus-Jensen K, Poethko T, Schottelius M, Hauser A, Schwaiger M, Wester HJ. Chemoselective hydrazone formation between HYNIC-functionalized peptides and 18F-fluorinated aldehydes. *Nucl Med Biol*. 2006 Feb;33(2):173-83.
49. Sprenger T, Valet M, Boecker H, Henriksen G, Spilker ME, Willoch F, Wagner KJ, Wester HJ, Tolle TR. Opioidergic activation in the medial pain system after heat pain. *Pain*. 2006 May;122(1-2):63-7.
48. Cescato R, Schulz S, Waser B, Eltschinger V, Rivier JE, Wester HJ, Culler M, Ginj M, Liu Q, Schonbrunn A, Reubi JC. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. *J Nucl Med*. 2006 Mar;47(3):502-11.
47. Baumgartner U, Buchholz HG, Bellosevich A, Magerl W, Siessmeier T, Rolke R, Hohnemann S, Piel M, Rosch F, Wester HJ, Henriksen G, Stoeter P, Bartenstein P, Treede RD, Schreckenberger M. High opiate receptor binding potential in the human lateral pain system. *Neuroimage*. 2006 Apr 15;30(3):692-9

46. Wester HJ, Kessler H. Molecular targeting with peptides or peptide-polymer conjugates: just a question of size? *J Nucl Med.* 2005 Dec;46(12):1940-5.
45. Henriksen G, Platzer S, Marton J, Hauser A, Berthele A, Schwaiger M, Marinelli L, Lavecchia A, Novellino E, Wester HJ. Syntheses, biological evaluation, and molecular modeling of ¹⁸F-labelled 4-anilodipiperidines as mu-opioid receptor imaging agents. *Med Chem.* 2005 Dec 1;48(24):7720-32.
44. Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, Weber WA, Schwaiger M. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer ¹⁸F-galacto-RGD in cancer patients. *J Nucl Med.* 2005 Aug;46(8):1333-41.
43. Gawaz M, Konrad I, Hauser AI, Sauer S, Li Z, Wester HJ, Bengel FM, Schwaiger M, Schomig A, Massberg S, Haubner R. Non-invasive imaging of glycoprotein VI binding to injured arterial lesions. *Thromb Haemost.* 2005 May;93(5):910-3.
42. Schottelius M, Reubi JC, Eltschinger V, Schwaiger M, Wester HJ. N-terminal sugar conjugation and C-terminal Thr-for-Thr(ol) exchange in radioiodinated Tyr³-octreotide: effect on cellular ligand trafficking in vitro and tumor accumulation in vivo. *J Med Chem.* 2005 Apr 21;48(8):2778-89.
41. Haubner R, Weber WA, Beer AJ, Vabulien E, Reim D, Sarbia M, Becker KF, Goebel M, Hein R, Wester HJ, Kessler H, Schwaiger M. Noninvasive visualization of the activated $\alpha v \beta 3$ integrin in cancer patients by positron emission tomography and [¹⁸F]Galacto-RGD. *PLoS Med.* 2005 Mar;2(3):e70.
40. Henriksen G, Platzer S, Hauser A, Willoch F, Berthele A, Schwaiger M, Wester HJ. ¹⁸F-labelled sufentanil for PET-imaging of μ -opioid receptors. *Bioorg Med Chem Lett.* 2005 Apr 1;15(7):1773-7.
39. Schottelius M, Rau F, Reubi JC, Schwaiger M, Wester HJ. Modulation of pharmacokinetics of radioiodinated sugar-conjugated somatostatin analogues by variation of peptide net charge and carbohydrate chemistry. *Bioconjug Chem.* 2005 Mar-Apr;16(2):429-37.
38. Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P, Wester HJ, Beck R, McEwan AJ, Wiebe LI, Schwaiger M. Hypoxia-specific tumor imaging with ¹⁸F-fluoroazomycin arabinoside. *J Nucl Med.* 2005 Jan;46(1):106-13.
37. Henriksen G, Herz M, Hauser A, Schwaiger M, Wester HJ. Synthesis and preclinical evaluation of the choline transport tracer deshydroxy-[¹⁸F]fluorocholeline ([¹⁸F]dOC). *Nucl Med Biol.* 2004 Oct;31(7):851-8.
36. Stahl A, Wieder H, Wester HJ, Piert M, Lordick F, Ott K, Rummeny E, Schwaiger M, Weber WA. PET/CT molecular imaging in abdominal oncology. *Abdom Imaging.* 2004 May-Jun;29(3):388-97. Review.
35. Henriksen G, Schottelius M, Poethko T, Hauser A, Wolf I, Schwaiger M, Wester HJ. Proof of principle for the use of ¹¹C-labelled peptides in tumour diagnosis with PET. *Eur J Nucl Med Mol Imaging.* 2004 Dec;31(12):1653-7.
34. Spilker ME, Sprenger T, Valet M, Henriksen G, Wagner K, Wester HJ, Toelle TR, Boecker H. Quantification of [¹⁸F]diprenorphine kinetics in the human brain with compartmental and non-compartmental modeling approaches. *Neuroimage.* 2004 Aug;22(4):1523-33.
33. Stahl A, Wieder H, Piert M, Wester HJ, Senekowitsch-Schmidtke R, Schwaiger M. Positron emission tomography as a tool for translational research in oncology. *Mol Imaging Biol.* 2004 Jul-Aug;6(4):214-24. Review.
32. Wester HJ, Schottelius M, Poethko T, Bruus-Jensen K, Schwaiger M. Radiolabeled carbohydrate somatostatin analogs: a review of the current status. *Cancer Biother Radiopharm.* 2004 Apr;19(2):231-44. Review.
31. Schottelius M, Poethko T, Herz M, Reubi JC, Kessler H, Schwaiger M, Wester HJ. First (¹⁸F)-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. *Clin Cancer Res.* 2004 Jun 1;10(11):3593-606.
30. Poethko T, Schottelius M, Thumshirn G, Hersel U, Herz M, Henriksen G, Kessler H, Schwaiger M, Wester HJ. Two-step methodology for high-yield routine radiohalogenation of peptides: (¹⁸F)-labeled RGD and octreotide analogs. *J Nucl Med.* 2004 May;45(5):892-902.
29. Haubner R, Wester HJ. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. *Curr Pharm Des.* 2004;10(13):1439-55. Review.
28. Willoch F, Schindler F, Wester HJ, Empl M, Straube A, Schwaiger M, Conrad B, Tölle TR. Central poststroke pain and reduced opioid receptor binding within pain processing circuitries: a [¹¹C]diprenorphine PET study. *Pain.* 2004 Apr;108(3):213-20.
27. Kuhnast B, Bodenstein C, Haubner R, Wester HJ, Senekowitsch-Schmidtke R, Schwaiger M, Weber WA. Targeting of gelatinase activity with a radiolabeled cyclic HWGF peptide. *Nucl Med Biol.* 2004 Apr;31(3):337-44.
26. Momose M, Reder S, Raffel DM, Watzlowik P, Wester HJ, Nguyen N, Elsinga PH, Bengel FM, Remien J, Schwaiger M. Evaluation of cardiac beta-adrenoreceptors in the isolated perfused rat heart using (S)-¹¹C-CGP12388. *J Nucl Med.* 2004 Mar;45(3):471-7.
25. Haubner R, Bruchertseifer F, Bock M, Kessler H, Schwaiger M, Wester HJ. Synthesis and biological evaluation of a (^{99m}Tc)-labelled cyclic RGD peptide for imaging the alphavbeta3 expression. *Nuklearmedizin.* 2004 Feb;43(1):26-32.
24. Haubner R, Kuhnast B, Mang C, Weber WA, Kessler H, Wester HJ, Schwaiger M. [¹⁸F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. *Bioconjug Chem.* 2004 Jan-Feb;15(1):61-9.
23. Haubner RH, Wester HJ, Weber WA, Schwaiger M. Radiotracer-based strategies to image angiogenesis. *Q J Nucl Med.* 2003 Sep;47(3):189-99. Review.

22. Vaidyanathan G, Friedman HS, Affleck DJ, Schottelius M, Wester HJ, Zalutsky MR. Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts. *Clin Cancer Res*. 2003 May;9(5):1868-76.
21. Wester HJ, Schottelius M, Scheidhauer K, Meisetschläger G, Herz M, Rau FC, Reubi JC, Schwaiger M. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrate analogue of octreotide. *Eur J Nucl Med Mol Imaging*. 2003 Jan;30(1):117-22.
20. Schottelius M, Wester HJ, Reubi JC, Senekowitsch-Schmidtke R, Schwaiger M. Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates. *Bioconjug Chem*. 2002 Sep-Oct;13(5):1021-30.
19. Rau FC, Weber WA, Wester HJ, Herz M, Becker I, Krüger A, Schwaiger M, Senekowitsch-Schmidtke R. O-(2-[(18F)Fluoroethyl]-L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes. *Eur J Nucl Med Mol Imaging*. 2002 Aug;29(8):1039-46.
18. Wester HJ, Schottelius M, Scheidhauer K, Reubi JC, Wolf I, Schwaiger M. Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydrate on the pharmacokinetics. *Eur J Nucl Med Mol Imaging*. 2002 Jan;29(1):28-38.
17. Weber WA, Haubner R, Vabulien E, Kuhnast B, Wester HJ, Schwaiger M. Tumor angiogenesis targeting using imaging agents. *Q J Nucl Med*. 2001 Jun;45(2):179-82. Review.
16. Schwaiger M, Wester HJ. Molecular imaging: dream or reality?. *Nuklearmedizin*. 2001 Jun;40(3):N19-22. Review. German.
15. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL, Senekowitsch-Schmidtke R, Kessler H, Schwaiger M. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. *Cancer Res*. 2001 Mar 1;61(5):1781-5.
14. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, Kessler H, Schwaiger M. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. *J Nucl Med*. 2001 Feb;42(2):326-36.
13. Willoch F, Rosen G, Tölle TR, Oye I, Wester HJ, Berner N, Schwaiger M, Bartenstein P. Phantom limb pain in the human brain: unraveling neural circuitries of phantom limb sensations using positron emission tomography. *Ann Neurol*. 2000 Dec;48(6):842-9.
12. Lohof E, Planker E, Mang C, Burkhart F, Dechantsreiter MA, Haubner R, Wester HJ, Schwaiger M, Hölzemann G, Goodman SL, Kessler H. Carbohydrate Derivatives for Use in Drug Design: Cyclic alpha(v)-Selective RGD Peptides. *Angew Chem Int Ed Engl*. 2000 Aug 4;39(15):2761-2764.
11. Wester HJ, Willoch F, Tölle TR, Munz F, Herz M, Oye I, Schadrack J, Schwaiger M, Bartenstein P. 6-O-(2-[18F]fluoroethyl)-6-O-desmethyldiprenorphine ([18F]DPN): synthesis, biologic evaluation, and comparison with [11C]DPN in humans. *J Nucl Med*. 2000 Jul;41(7):1279-86.
10. Weber WA, Wester HJ, Grosu AL, Herz M, Dzewas B, Feldmann HJ, Molls M, Stöcklin G, Schwaiger M. O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. *Eur J Nucl Med*. 2000 May; 27(5):542-9.
9. Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H, Stöcklin G, Schwaiger M. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. *J Nucl Med*. 1999 Jun; 40(6):1061-71.
8. Heiss P, Mayer S, Herz M, Wester HJ, Schwaiger M, Senekowitsch-Schmidtke R. Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo. *J Nucl Med*. 1999 Aug; 40(8):1367-73.
7. Wester HJ, Herz M, Senekowitsch-Schmidtke R, Schwaiger M, Stöcklin G, Hamacher K. Preclinical evaluation of 4-[18F]fluoroprolines: diastereomeric effect on metabolism and uptake in mice. *Nucl Med Biol*. 1999 Apr; 26(3):259-65.
6. Willoch F, Tölle TR, Wester HJ, Munz F, Petzold A, Schwaiger M, Conrad B, Bartenstein P. Central pain after pontine infarction is associated with changes in opioid receptor binding: a PET study with 11C-diprenorphine. *AJNR Am J Neuroradiol*. 1999 Apr;20(4):686-90.
5. Schadrack J, Willoch F, Platzer S, Bartenstein P, Mahal B, Dworzak D, Wester HJ, Zieglgänsberger W, Tölle TR. Opioid receptors in the human cerebellum: evidence from [11C]diprenorphine PET, mRNA expression and autoradiography. *Neuroreport*. 1999 Feb 25;10(3):619-24.
4. Wester HJ, Herz M, Weber W, Heiss P, Senekowitsch-Schmidtke R, Schwaiger M, Stöcklin G. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. *J Nucl Med*. 1999 Jan; 40(1):205-12.
3. Wester HJ, Brockmann J, Rösch F, Wutz W, Herzog H, Smith-Jones P, Stolz B, Bruns C, Stöcklin G. PET-pharmacokinetics of 18F-octreotide: a comparison with 67Ga-DFO- and 86Y-DTPA-octreotide. *Nucl Med Biol*. 1997 May; 24(4):275-86.
2. Wester HJ, Hamacher K, Stöcklin G. A comparative study of N.C.A. fluorine-18 labeling of proteins via acylation and photochemical conjugation. *Nucl Med Biol*. 1996 Apr; 23(3):365-72.
1. Guhlke S, Wester HJ, Bruns C, Stöcklin G. (2-[18F]fluoropropionyl-(D)phe1)-octreotide, a potential radiopharmaceutical for quantitative somatostatin receptor imaging with PET: synthesis, radiolabeling, in vitro validation and biodistribution in mice. *Nucl Med Biol*. 1994 Aug; 21(6):819-25.

Books/ Book Chapters

1. Stöcklin G., Wester HJ. 1998, „Strategies for radioligand development“, In: Positron Emission Tomography: A Critical Assessment of Recent Trends“. Gulyas B and Müller-Gärtner HW (editors), p57-90, Kluwer academic Publishers, ISBN 0-7923-5091-x
2. Rösch F., Wester HJ, DeGrado T. 2000, "Current Developments of 18F-Labeled Tracers in Oncology", In: PET in Clinical Oncology, H-J. Wieler, R.E.Coleman (editors); Steinkopf Verlag, ISBN 3-7985-1219-1.
3. Wester HJ, 2003, "18F-labeling Chemistry and Labeled Compounds", In: Nuclear Chemistry Handbook, Vol.4; A. Vertes, S. Nagy, Z. Klencsar (editors), p167-202, Kluwer Academic Publishers, ISBN 1-4020-1316-7
4. Wester HJ, Schottelius M, 2006, "Fluorine-18 labeling of peptides", In: PET Chemistry, The driving force in Molecular Imaging. PA Schubiger, L.Lehmann, M.Wiebe (editors), p79-112, Springer Verlag, ISBN 13-978-3-540-32623-6
5. Wester HJ, Schottelius M, 2007, „Radiopharmaka für die nukleare Onkologie“, in: Nuklearmedizinische Onkologie. BJ. Krause, A. Buck, M. Schwaiger (editors), p87-106, Verlagsgruppe Hüthig Jehle Rehm, ISBN 978-3-609-76308-8
6. Dijkgraaf I, Wester HJ, 2008, "Peptides, Multimers and Polymers", In: Handbook of Experimental Pharmacology, Molecular Imaging II; W. Semmler, M.Schwaiger (editors), p61-92, Springer Verlag, ISBN 978-3-540-77449-5
7. Dijkgraaf I, Schottelius M, Wester HJ, 2008. "F-18 labeling of peptides and proteins". In: Recent Advances of Bioconjugation Chemistry in Molecular Imaging, Chen X (editor); ISBN: 978-81-308-0210-7
8. Auernheimer J, Schottelius M, Wester HJ, 2008, "Carbohydration of radiolabeled peptides", In: Recent Advances of Bioconjugation Chemistry in Molecular Imaging, Chen X (editor); ISBN: 978-81-308-0210-7
10. Wester HJ (editor). Munich Molecular Imaging Handbook Series, Vol 1. Pharmaceutical Radiochemistry (I) ISBN 978-3-9813523-0-6

Patents / Patent Applications

11 Patents and Patent Applications